0001520138-21-000255.txt : 20210510 0001520138-21-000255.hdr.sgml : 20210510 20210510161618 ACCESSION NUMBER: 0001520138-21-000255 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210510 DATE AS OF CHANGE: 20210510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 21907422 BUSINESS ADDRESS: STREET 1: 2120 COLORADO AVE. STREET 2: SUITE 230 CITY: LOS ANGELES STATE: CA ZIP: 90404 BUSINESS PHONE: 310-444-4300 MAIL ADDRESS: STREET 1: 2120 COLORADO AVE. STREET 2: SUITE 230 CITY: LOS ANGELES STATE: CA ZIP: 90404 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20210331_10q.htm FORM 10-Q FOR PERIOD ENDING MARCH 31, 2021
0001580149 false 2021 Q3 --06-30 0001580149 2020-07-01 2021-03-31 0001580149 2021-05-07 0001580149 2021-03-31 0001580149 2020-06-30 0001580149 2021-01-01 2021-03-31 0001580149 2020-01-01 2020-03-31 0001580149 2019-07-01 2020-03-31 0001580149 2019-06-30 0001580149 2020-03-31 0001580149 us-gaap:CommonStockMember 2019-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001580149 us-gaap:RetainedEarningsMember 2019-06-30 0001580149 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001580149 2019-07-01 2019-09-30 0001580149 us-gaap:CommonStockMember 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-09-30 0001580149 2019-09-30 0001580149 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001580149 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001580149 2019-10-01 2019-12-31 0001580149 us-gaap:CommonStockMember 2019-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001580149 us-gaap:RetainedEarningsMember 2019-12-31 0001580149 2019-12-31 0001580149 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001580149 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001580149 us-gaap:CommonStockMember 2020-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001580149 us-gaap:RetainedEarningsMember 2020-03-31 0001580149 us-gaap:CommonStockMember 2020-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001580149 us-gaap:RetainedEarningsMember 2020-06-30 0001580149 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001580149 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001580149 2020-07-01 2020-09-30 0001580149 us-gaap:CommonStockMember 2020-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001580149 us-gaap:RetainedEarningsMember 2020-09-30 0001580149 2020-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001580149 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001580149 2020-09-01 2020-12-31 0001580149 us-gaap:CommonStockMember 2020-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001580149 us-gaap:RetainedEarningsMember 2020-12-31 0001580149 2020-12-31 0001580149 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001580149 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001580149 us-gaap:CommonStockMember 2021-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001580149 us-gaap:RetainedEarningsMember 2021-03-31 0001580149 us-gaap:StockOptionMember 2021-03-31 0001580149 us-gaap:StockOptionMember 2020-03-31 0001580149 us-gaap:WarrantMember 2021-03-31 0001580149 us-gaap:WarrantMember 2020-03-31 0001580149 bivi:AcuitasGroupHoldingsLLCMember 2020-09-22 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember 2021-03-31 0001580149 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001580149 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001580149 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember 2020-06-30 0001580149 us-gaap:FairValueInputsLevel1Member 2020-06-30 0001580149 us-gaap:FairValueInputsLevel2Member 2020-06-30 0001580149 us-gaap:FairValueInputsLevel3Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-09-24 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-09-22 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2020-09-22 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-09-24 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-09-22 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2020-09-22 0001580149 us-gaap:StockOptionMember 2020-06-30 0001580149 us-gaap:StockOptionMember 2020-07-01 2021-03-31 0001580149 us-gaap:StockOptionMember 2019-07-01 2020-03-31 0001580149 us-gaap:StockOptionMember srt:DirectorMember 2020-07-01 2021-03-31 0001580149 bivi:StockOption1Member 2021-03-31 0001580149 bivi:StockOption1Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption2Member 2021-03-31 0001580149 bivi:StockOption2Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption3Member 2021-03-31 0001580149 bivi:StockOption3Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption4Member 2021-03-31 0001580149 bivi:StockOption4Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption5Member 2021-03-31 0001580149 bivi:StockOption5Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption6Member 2021-03-31 0001580149 bivi:StockOption6Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption7Member 2021-03-31 0001580149 bivi:StockOption7Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption8Member 2021-03-31 0001580149 bivi:StockOption8Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption9Member 2021-03-31 0001580149 bivi:StockOption9Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption10Member 2021-03-31 0001580149 bivi:StockOption10Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption11Member 2021-03-31 0001580149 bivi:StockOption11Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption12Member 2021-03-31 0001580149 bivi:StockOption12Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption13Member 2021-03-31 0001580149 bivi:StockOption13Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption14Member 2021-03-31 0001580149 bivi:StockOption14Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption15Member 2021-03-31 0001580149 bivi:StockOption15Member 2020-07-01 2021-03-31 0001580149 us-gaap:WarrantMember 2020-06-30 0001580149 us-gaap:WarrantMember 2020-07-01 2021-03-31 0001580149 us-gaap:CommonStockMember 2020-07-27 2020-07-28 0001580149 2020-07-27 2020-07-28 0001580149 us-gaap:CommonStockMember 2021-01-26 2021-01-27 0001580149 2021-01-26 2021-01-27 0001580149 us-gaap:CommonStockMember 2021-03-22 2021-03-23 0001580149 2021-03-22 2021-03-23 0001580149 us-gaap:CommonStockMember 2021-03-22 2021-03-24 0001580149 2021-03-22 2021-03-24 0001580149 us-gaap:WarrantMember 2020-07-12 2020-07-13 0001580149 us-gaap:WarrantMember 2020-09-21 2020-09-22 0001580149 us-gaap:StockOptionMember 2020-09-29 2020-10-02 0001580149 us-gaap:StockOptionMember 2020-10-12 2020-10-13 0001580149 us-gaap:StockOptionMember 2020-12-17 2020-12-18 0001580149 us-gaap:StockOptionMember 2021-01-18 2021-01-19 0001580149 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-04-18 2021-04-19 0001580149 us-gaap:SubsequentEventMember 2021-04-18 2021-04-19 0001580149 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-04-29 2021-04-30 0001580149 us-gaap:SubsequentEventMember 2021-04-29 2021-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

Form 10-Q

(Mark One) 

☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2021

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 001-39015

BIOVIE INC.

(Exact name of registrant as specified in its charter)

Nevada   46-2510769
(State or other jurisdiction of 
incorporation or organization)		   (I.R.S. Empl. Ident. No.)

 

2120 Colorado Avenue Suite 230
Santa Monica, CA 90404
(Address of principal executive offices, Zip Code)
 
(310)-444-4300
(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share BIVI The NASDAQ Stock Market, LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒                                          No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒                                          No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer  ☐ Accelerated filer  ☐
Non-accelerated Filer  ☒ Smaller reporting company  ☒
    Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐                                          No ☒

 

There were 13,958,516 shares of the Registrant’s $0.0001 par value Class A common stock outstanding as of May 7, 2021.

 
 
 
 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements 1
  Condensed Balance Sheets at March 31, 2021 (unaudited) and June 30, 2020 1
  Condensed Statements of Operations (unaudited) - for the three months and nine months ended March 31, 2021 and 2020 2
  Condensed Statements of Cash Flows (unaudited) - for the nine months ended March 31, 2021 and 2020 3
  Condensed Statements of Changes in Stockholders’ Equity/(Deficit) (unaudited) – for the periods from July 1, 2019 through March 31, 2020 and July 1, 2020 through March 31, 2021 4
  Notes to Unaudited Condensed Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 23
Item 4. Controls and Procedures 23

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings 24
Item 1A. Risk Factors 24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
Item 3. Defaults Upon Senior Securities 24
Item 4. Mine Safety Disclosures 24
Item 5. Other Information 24
Item 6. Exhibits 25
     
SIGNATURES 26

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

 

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc.

 

 
 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

BioVie Inc.

Condensed Balance Sheets 

 

   March 31,  June 30,
   2021  2020
ASSETS   (Unaudited)      
           
CURRENT ASSETS:          
Cash  $11,351,258   $37,195 
Other assets   42,855    375,785 
Total current assets   11,394,113    412,980 
           
OTHER  ASSETS:          
Intangible assets, net   1,153,194    1,325,226 
Goodwill   345,711    345,711 
Total other assets   1,498,905    1,670,937 
           
TOTAL ASSETS  $12,893,018   $2,083,917 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $1,428,434   $1,259,206 
Derivative liability - warrants   —      16,411,504 
Derivative liability - conversion option on convertible debenture   —      5,000,800 
Convertible debenture - related party, net of unearned discount of $0 and $462,864 and capitalized accrued interest of $0 and $48,407 at March 31, 2021 and June 30, 2020, respectively   —      848,543 
Total current liabilities   1,428,434    23,520,053 
           
Loan payable   62,500    62,500 
           
TOTAL LIABILITIES   1,490,934    23,582,553 
           
Commitments and contingencies (Note 8)          
           
STOCKHOLDERS' EQUITY (DEFICIT)          
           
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding   —      —   
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2021 and June 30, 2020; 13,957,792 and 5,204,392 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively   1,395    520 
Additional paid in capital   104,753,666    19,538,742 
Accumulated deficit   (93,352,977)   (41,037,898)
Total stockholders' equity (deficit)   11,402,084    (21,498,636)
           
TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY (DEFICIT)  $12,893,018   $2,083,917 

 

See accompanying notes to unaudited condensed financial statements

 

-1-

BioVie Inc.

Condensed Statements of Operations

(Unaudited)

 

   Three Months Ended   Nine Months Ended
   March 31 2021  March 31 2020  March 31 2021  March 31 2020
             
OPERATING EXPENSES:                    
Amortization expense  $57,344   $57,344   $172,032   $172,032 
Research and development expenses   696,657    353,198    1,759,769    1,003,124 
Selling, general and administrative expenses   2,247,510    288,711    4,519,830    940,762 
TOTAL OPERATING EXPENSES   3,001,511    699,253    6,451,631    2,115,918 
                     
LOSS FROM OPERATIONS   (3,001,511)   (699,253)   (6,451,631)   (2,115,918)
                     
OTHER (INCOME) EXPENSE:                    
Change in fair value of derivative liabilities   —      (366,550)   (8,279,919)   (8,125,328)
Interest expense   —      33,699    559,455    3,532,234 
Interest income   (8,643)   —      (14,408)   (233)
TOTAL OTHER (INCOME) EXPENSE, NET   (8,643)   (332,851)   (7,734,872)   (4,593,327)
                     
                     
NET (LOSS) INCOME  $(2,992,868)  $(366,402)  $1,283,241   $2,477,409 
                     
Deemed dividends - Related Party   —      —      53,598,320    17,099,058 
                     
NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS  $(2,992,868)  $(366,402)  $(52,315,079)  $(14,621,649)
                     
NET (LOSS) INCOME PER COMMON SHARE                    
- Basic  $(0.22)  $(0.07)  $(4.64)  $(3.02)
- Diluted  $(0.22)  $(0.07)  $(4.64)  $(3.02)
                     
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING                    
- Basic   13,919,933    5,199,003    11,269,212    4,839,802 
- Diluted   13,919,933    5,199,003    11,269,212    4,839,802 

 

See accompanying notes to unaudited condensed financial statements

 

-2-


BioVie Inc.

Condensed Statements of Cash Flows

(Unaudited)

   Nine Months Ended
   March 31, 2021  March 31, 2020
       
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income  $1,283,241   $2,477,409 
Adjustments to reconcile net income to net cash used in operating activities:          
Amortization of intangible assets   172,032    172,032 
Stock based compensation   2,340,533    24,846 
Common shares issued for interest payment   —      13,487 
Common shares issued for service   —      39,200 
Interest expense from convertible debenture   537,275    3,516,537 
Change in fair value of derivative liabilities   (8,279,919)   (8,125,328)
Changes in operating assets and liabilities          
Other assets   332,930    (243,030)
Accounts payable and accrued expenses   169,228    856,639 
Net cash used in operating activities   (3,444,680)   (1,268,208)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Net proceeds from issuance of common stock   15,628,010    —   
Proceeds from exercise of warrants   516,551    —   
Payment of convertible debenture - related party   (1,821,818)   —   
Proceeds from loan payable - related party   —      432,000 
Proceeds from convertible debenture - related party   436,000    500,000 
Net cash provided by financing activities   14,758,743    932,000 
           
Net  increase (decrease) in cash   11,314,063    (336,208)
           
Cash, beginning of period   37,195    339,923 
           
Cash, end of period  $11,351,258   $3,715 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $22,180   $2,212 
Cash paid for taxes  $—     $—   
           
SCHEDULE OF NON-CASH FINANCING ACTIVITIES:          
Deemed dividends - related party  $53,598,320   $17,099,058 
Stock warrants classified as derivative liability  $—     $7,530,308 

 

See accompanying notes to unaudited condensed financial statements

 

-3-

BioVie Inc.

Condensed Statements of Changes in Stockholders’ (Deficit) Equity

For the periods July 1, 2019 through March 31, 2020 and July 1, 2020 through March 31, 2021

(Unaudited)

                         
   Common Stock   Additional Paid in  Accumulated  Total Stockholders' Equity
   Shares  Amount  Capital  Deficit  (Deficit)
                
Balance, June 30, 2019   4,058,724   $406   $9,392,573   $(7,262,072)  $2,130,907 
                          
Issuance of commitment shares   1,125,000    112    10,068,638    —      10,068,750 
                          
Deemed dividend for commitment shares   —      —      —      (17,099,058)   (17,099,058)
                          
Net loss for the three months ended September 30, 2019   —      —      —      (3,821,227)   (3,821,227)
                          
Balance, September 30, 2019   5,183,724    518    19,461,211    (28,182,357)   (8,720,628)
                          
Stock option compensation   —      —      11,162    —      11,162 
                          
Net income for the three months ended December 31, 2019   —      —      —      6,665,038    6,665,038 
                          
Balance, December 31, 2019   5,183,724   $518   $19,472,373   $(21,517,319)  $(2,044,428)
                          
Stock based compensation   —      —      13,684    —      13,684 
                          
Issuance of shares for services   11,200    1    39,199    —      39,200 
                          
Issuance of shares for interest payment   4,422    —      13,487    —      13,487 
                          
Net loss for the three months ended March 31, 2020   —      —      —      (366,402)   (366,402)
                          
Balance, March 31, 2020   5,199,346   $519   $19,538,743   $(21,883,721)  $(2,344,459)
                          
Balance, June 30, 2020   5,204,392   $520   $19,538,742   $(41,037,898)  $(21,498,636)
                          
Net proceeds from issuance of common stock   1,799,980    180    15,627,830    —      15,628,010 
                          
Redemption of warrants  - related party   1,549,750    155    13,132,230    —      13,132,385 
                          
Deemed dividend for purchase option - related party   5,359,832    536    53,597,784    (53,598,320)   —   
                          
Cashless exercise of options   2,210    —      —      —      —   
                          
Net income for the three months ended September 30, 2020   —      —      —      7,333,916    7,333,916 
                          
Balance, September 30, 2020   13,916,164    1,391    101,896,586    (87,302,302)   14,595,675 
                          
Stock based compensation   —      —      1,536,929    —      1,536,929 
                          
Net loss for the three months ended December 31, 2020   —      —      —      (3,057,807)   (3,057,807)
                          
Balance, December 31, 2020   13,916,164   $1,391   $103,433,515   $(90,360,109)  $13,074,797 
                          
Stock based compensation   —      —      803,604    —      803,604 
                          
Cashless exercise of warrants   304    —      —      —      —   
                          
Proceeds from exercise of warrants   41,324    4    516,547    —      516,551 
                          
Net loss for the three months ended March 31, 2021   —      —      —      (2,992,868)   (2,992,868)
                          
Balance, March 31, 2021   13,957,792   $1,395   $104,753,666   $(93,352,977)  $11,402,084 

 

See accompanying notes to unaudited condensed financial statements

 

-4-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

1. Background Information

 

BioVie Inc. (the “Company”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

 

BioVie completed a Phase 2a clinical trial of BIV201 in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute in Richmond, VA in 2019. The Company met with representatives of the Food and Drug Administration (“FDA”) in a Type C Guidance Meeting to discuss the study results and plan our next clinical study. Subsequently we requested a Type B Meeting and submitted an extensive pre-meeting information package. In April 2020, the FDA provided a written response that provided new guidance regarding primary and secondary endpoints, BIV201 dosing levels, quality of life measures and other key aspects of the clinical trial design. After further communications, the Company completed the clinical trial design protocol and was cleared to begin a Phase 2 clinical study. We activated the first trial sites in the first calendar quarter of 2021 and patient screening is now underway. The Phase 2 study results will be used to guide the design of a pivotal Phase 3 clinical trial. We have developed a patent-pending novel liquid formulation of BIV201 for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version of terlipressin.

 

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company is applying for global patent coverage of a proprietary liquid formulation of terlipressin for use in the Phase 2 and Phase 3 clinical trials, which has been cleared by the FDA. This could eventually provide up to 20 years of patent protection in countries where the Company seeks patent issuance according to local patent laws.

 

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the  rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

 

On April 27, 2021, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with NeurMedix, Inc. (“NeurMedix”) and Acuitas Group Holdings, LLC (“Acuitas”), which are related party affiliates, pursuant to which the Company has agreed to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration of cash and shares of common stock. (collectively, the “Transaction”). The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease. See Note 9 - Subsequent Events.

 

-5-

 BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

2. Liquidity

 

Liquidity and Going Concern

 

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2021, the Company had working capital of approximately $10 million and cash of $11.4 million and, stockholders’ equity was approximately $11.4 million, and its accumulated deficit was approximately $93.4 million. In addition, the Company has not generated any revenues and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. The emergence of widespread health emergencies or pandemics of the coronavirus ("Covid-19"), may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability, including the duration and spread of the outbreak and restrictions and the impact of Covid-19 on the financial markets and the overall economy, all of which are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds may be materially adversely affected.

Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3. Significant Accounting Policies

 

Basis of Presentation – Interim Financial Information

These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2020 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2020 and 2019 in our Annual Report on form 10-K filed with Securities Exchange Commission (“SEC”) on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10K for the fiscal year ended June 30, 2020 filed with the SEC on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020.

-6-

 BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited) 

 

3. Significant Accounting Policies (continued)

 

Loan Pursuant to Paycheck Protection Program

 

The Company received $62,500 in loan proceeds pursuant to the Paycheck Protection Program (“PPP”), under the Coronavirus Aid Relief and Economic Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement by and between the Company and Lender. The Company applied for the loan in May 2020 and received funding for its maximum amount of $62,500 on May 21, 2020. The term of the loan is for 60 months and matures on the fifth-year anniversary from the date of funding. It bears interest at an annual rate of 1%. The PPP loan is subject to 100% forgiveness. The Company has filed the application for forgiveness, in February 2021 and is pending confirmation of forgiveness by the SBA. There can be no assurance that such forgiveness will occur. The Company is accounting for the loan as debt and if forgiveness is granted the Company will recognize a gain on extinguishment.

   

Net (loss) income per Common Share

 

Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the nine months ended March 31, 2021 and 2020, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liability creating a net loss available to common shareholders. For the three months ended March 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to net loss for the period.

The table below shows the number of outstanding stock options and warrants as of March 31, 2021 and 2020:

   March 31, 2021  March 31, 2020
   Number of Shares  Number of Shares
Stock Options   755,200    68,400 
Warrants   173,021    1,374,667 
Total   928,221    1,443,067 

 

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. This ASU was adopted as of July 1, 2020. There has been no impact to its condensed financial statements and related disclosures.

 

-7-

 BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited) 

  

4. Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of March 31, 2021 and June 30, 2020:

   March 31, 2021  June 30, 2020
Intellectual Property  $2,293,770   $2,293,770 
Less Accumulated Amortization   (1,140,576)   (968,544)
Intellectual Property, Net  $1,153,194   $1,325,226 

 

Amortization expense for the three-month period ended March 31, 2021 and 2020 was $57,344 and $57,344 respectively. Amortization expense for the nine-month period ended March 31, 2021 and 2020 was $172,032 and $172,032 respectively.

 

Estimated future amortization expense is as follows:

 

   
Year ending June 30, 2021 (Remaining three months)  $                           57,344
2022                             229,377
2023                             229,377
2024                             229,377
2025                             229,377
2026                             178,342
Intellectual Property, Net  $                      1,153,194

 

-8-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

5. Related Party Transactions

 

Equity Transactions with Acuitas

 

On September 22, 2020, concurrent with the closing of the Company’s Offering, approximately $1.8 million was paid to Acuitas satisfying all amounts owed on the Debenture due September 24, 2020 held by the Company’s controlling stockholder, Acuitas.

 

Additionally in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of 6,909,582 shares of Common Stock to Acuitas, representing (i) 5.4 million shares issuable pursuant to Acuitas’ rights under the Purchase Agreement dated July 3, 2018, as amended on June 24, 2019 and October 9, 2019; and the various extension letters as more fully described below; which resulted in a deemed dividend at the close of the public offering at price of $10 per share, consistent with the Company’s accounting policy; and (ii) the automatic exercise of 1.5 million warrants issued to Acuitas in connection with the Debenture financing at the par value of the Common Stock.

 

During the three months ended September 30, 2020, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September 22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which 328,250 warrants had been issued. In accordance with the Debenture agreements, as more fully described below; at September 22, 2020 upon the Company’s close of its public offering, al1 the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional 96,500 shares common stock issued to Acuitas.

 

The following paragraphs summarize the background of those financings and arrangements which were settled and redeemed on September 22, 2020.

 

On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.

 

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us. 

 

-9-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

5. Related Party Transactions (continued)

 

Each share of Preferred Stock automatically converted into 1 share of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.

 

Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:

 

-  

Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock; 

 

-  

Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq; 

 

-   Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.

 

-10-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)  

 

5. Related Party Transactions (continued)

 

Convertible Debenture Transaction with Acuitas

 

On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s current reverse stock split or December 1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants.

 

Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.

 

The issuance of 1,125,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the year ended June 30, 2020, accordingly. A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of the unearned discount for the three-month period ended March 31, 2021 and 2020 of $0 and $20,307, respectively, and for the nine months period ended March 31, 2021 and 2020 of $21,336 and $41,902, respectively.

 

The Company received draws under the Debenture that totaled approximately $1.3 million during the year ended June 30, 2020. The total interest expense related to the draws under the Debenture was approximately $99,000 for the year ended June 30, 2020. On April 1, 2020, the Company entered an amendment to modify the payment of accrued interest amounts under the original terms of the Debenture to capitalize all such amounts as would otherwise accrue on the Debenture. On January 4, 2020, payment of $13,487 accrued interest due was paid through the issuance of 4,422 shares of the Company’s common stock. Acuitas and the Company continue to discuss the need and timing for some or all the remaining draws under the Debenture Agreement. Subsequent to the initial $500,000 draw on September 24, 2019, the Company received draws that totaled $813,000 as July 13, 2020, and accordingly; the Company issued additional Bridge Warrants to purchase 203,250 shares of common stock to its controlling stockholder under the terms of the Bridge Financing. Accordingly, on April 16, 2020, the Company recorded the warrants to purchase 125,000 common stock related to the second $500,000 draw under the debenture as a derivative warrant liability as of June 30, 2020. The Company recorded the warrants related to the draws totaling $313,000 to purchase 78,250 common shares as derivative liabilities.

 

-11-

 BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)  

 

5. Related Party Transactions (continued)

 

Pursuant to the 2019 Purchase Agreement, Acuitas agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.

 

Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:

 

  - The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;

 

  - Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and

 

  - The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto.

 

On July 14, 2020, the Company, entered into a further extension of its letter agreements dated April 8, 2020, that furthered extended its letter agreement dated February 10, 2020 with Acuitas regarding Acuitas’ previous agreement to modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life of the Company’s intellectual property rights and commitment to purchase such securities upon the closing of the Offering and commitment to purchase such additional securities would remain effective until October 31, 2020, and accordingly Acuitas was entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company’s current bridge financing with Acuitas were to be made based with respect to the Company’s ongoing capital requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith. The letter agreement of July 14, 2020 also confirmed the understanding between the Company and Acuitas regarding certain amounts funded to BioVie that were intended as “partial draws” of credit available under the Debenture which, as of July 14, 2020 hereof aggregated $813,000 in aggregate principal amount in additional to amounts initial funded under the Debenture. Accordingly, such “partial draws” accrued additional principal as amounts otherwise funded pursuant to the original schedule of draws included in the Debenture (as modified by the letter agreement between BioVie and Acuitas dated April 1, 2020 regarding the capitalization of interest otherwise payable) and shall entitle Acuitas to receive a pro rata amount of Bridge Warrants.

 

-12-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

  

6. Fair Value Measurements

 

On September 22, 2020, concurrent with the closing of the Offering; the warrants related to derivative liabilities were automatically exercised in full and the convertible Debenture was paid off in cash expiring the conversion option. The fair value of the derivative liabilities - warrants and derivative liability - conversion option on convertible Debenture prior to redemption at September 22, 2020 was $13.1 million, and the change in the fair value of $8.3 million from June 30, 2020 was recorded in the accompanying condensed Statements of Operations. At September 22, 2020, the derivative liabilities, both the warrants and expired conversion option totaling $ 13.1 million were then recorded as additional paid in capital upon automatic exercise of the warrants and payoff of the Debenture.

 

At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

 

    Fair Value Measurements at
March 31, 2021
    Level 1    Level 2    Level 3    Total
                    
Derivative liability - Warrants  $—     $—     $—     $—  
Derivative liability -Conversion option on convertible debenture   —      —      —      —  
   Total derivatives  $—     $—     $—     $—  

 

   Fair Value Measurements at
   June 30, 2020
   Level 1  Level 2  Level 3  Total
             
Derivative liability - Warrants  $—     $—     $16,411,504   $16,411,504 
Derivative liability -Conversion option on convertible debenture   —      —      5,000,800    5,000,800 
   Total derivatives  $—     $—     $21,412,304   $21,412,304 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the nine months ended March 31, 2021:

  

   Derivative liabilities - Warrants  Derivative liability - Conversion Option on Convertible Debenture
       
Beginning balance at July 1, 2020  $16,411,504   $5,000,800 
Additions to level 3 liabilities   —      —   
Change in in fair value of level 3 liability   (6,054,121)   (2,225,798)
Transfer in and/or out of Level 3   (10,357,383)   (2,775,002)
Balance at March 31, 2021  $—     $—   

 

-13-


BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

6. Fair Value Measurements (continued)

 

Derivative liability – Warrants

 

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise. 

 

The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model. The valuation at June 30, 2020 used the following assumptions: stock price of $14, exercise price of $4.00, term of 5 year expiring April 2025, volatility of 76.61%, dividend yield of 0%, and risk-free interest rate of 0.29%.

 

The valuation at September 22, 2020 of the warrants associated with equity financing prior to their automatic exercise in full used were the following assumptions: stock price of $9.55, exercise price of $4.00, term of 4 year expiring September 2024, volatility of 79.69%, dividend yield of 0%, and risk-free interest rate of 0.21%. (See note 5 “Related Party Transactions”)

 

Derivative liability – Conversion option in convertible debenture

The Company recognized a derivative liability for the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture; which may be convertible into shares of common stock at $4.00 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The valuation at June 30, 2020 used the following assumptions: stock price of $14, conversion price of $4.00, term of 0.25 year expiring September 2020, volatility of 62.47%, dividend yield of 0%, and risk-free interest rate of 0.16%.

 

The valuation at September 22, 2020 used the following assumptions: stock price of $9.55, conversion price of $4.00, term of 0.008 year expiring September 2020, volatility of 45.49%, dividend yield of 0%, and risk-free interest rate of 0.01%.

 

The related Debenture was paid off in cash on September 22, 2020, expiring the conversion option. (See note 5 “Related Party Transactions”)

 

-14-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

7. Equity Transactions

 

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2021:

 

   Options  Weighted-Average Exercise Price  Weighted Remaining Average Contractual Term  Aggregate Intrinsic Value
Outstanding at June 30, 2020   60,400   $11.06    4.2   $352,600 
Granted   698,000    14.63    4.7    954,239 
Options Exercised or Forfeited   (3,200)   4.76    —      —   
Outstanding at March 31, 2021   755,200   $13.85    4.4   $1,516,511 
Exercisable at March 31, 2021   236,500   $13.85    4.4   $1,516,511 

 

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions for the nine months ended March 31, 2021 and 2020:

 

  March 31, 2021   March 31, 2020
Expected life of options (In years) 5   5
Expected volatility 77.05%   73.74%
Risk free interest rate 0.5%   1.63%
Dividend Yield 0%   0%

 

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $803,604 and $2,340,533 for the three- and nine- month periods ended March 31, 2021, respectively, and $13,684 and $24,846 for the three- and nine- month periods ended March 31, 2020, respectively.

As of March 31, 2021, unrecognized stock-based compensation cost was $3,721,620 which is expected to be recognized over a weighted-average period of approximately 3 years.

-15-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

7. Equity Transactions (continued)

 

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2021:

 

Exercise Price  Outstanding  Weighted Average Contract Life  Exercisable
$2.80    7,200    3.8    7,200 
$3.75    4,800    2.8    4,800 
$6.25    1,600    2.6    1,600 
$7.50    25,600    4.9    25,600 
$8.75    1,600    3.0    1,600 
$9.54    800    4.5    800 
$9.90    800    4.5    800 
$12.50    4,000    1.8    4,000 
$13.91    691,600    4.7    172,900 
$25.00    1,600    1.5    1,600 
$26.25    4,400    1.1    4,400 
$27.50    800    1.0    800 
$28.75    1,600    1.4    1,600 
$31.25    4,000    0.6    4,000 
$42.09    4,800    4.8    4,800 

 

Stock Warrants

 

The following table summarizes the warrants activity during the nine months ended March 31, 2021:

 

   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Life (Years)  Aggregate Intrinsic Value
Outstanding and exercisable at June 30, 2020   1,374,667   $7.72    4.2   $13,799,331 
Granted   293,248   $6.61    5.0   $—   
Expired   —     $—      —     $—   
Exercised   (41,644)  $12.40    4.0   $—   
Exercised - Acuitas   (1,453,250)  $4.00    4.0   $—   
Outstanding and exercisable at March 31, 2020   173,021   $10.49    3.4   $2,203,264 

 

Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,815 expire in fiscal year ending June 30, 2023, 110,140 expire in fiscal year ending June 30, 2025 and 48,675 expire in fiscal year ending June 30, 2026. 

 

-16-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

7. Equity Transactions (continued)

 

Issuance of common stock through exercise of Stock Options and Warrants

On July 28, 2020, the Company issued 2,210 shares of common stock pursuant to a cashless exercise of stock options to purchase 3,200 shares at an average exercise price of $4.76 per share.

 

On January 27, 2021, the Company issued 304 shares of common stock pursuant to a cashless exercise of warrants to purchase 320 shares at an average exercise price of $1.88 per share.

 

On March 23, 2021, the Company issued 27,000 shares of common stock pursuant to a cash exercise of warrants to purchase 27,000 shares at an average exercise price of $12.50 per share.

 

On March 24, 2021, the Company issued 14,324 shares of common stock pursuant to a cash exercise of warrants to purchase 14,324 shares at an average exercise price of $12.50 per share.

 

Issuance of warrants

On July 13, 2020, the Company issued Warrants to purchase 203,250 shares of common stock to its controlling stockholder under the terms of the Bridge Financing. The warrants were exercisable at an exercise price of $4 at any time from the date of issuance until 5 years from the date of issuance. (See Note 5 Related Party Transactions.)

On September 22, 2020, the Company issued warrants to purchase 89,998 shares of common stock to the underwriters of the Offering in connection with the close of the Offering of registered Common Stock The warrants are exercisable at an exercise price of $12.50 at any time from date of issuance until 5 years from the date of issuance.

Issuance of stock options

On October 1, 2020, the Company issued stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $9.54 at any time from date of issuance and expire 5 years from the date of issuance.

 

On October 13, 2020, the Company issued stock options to purchase 800 shares of common stock as part of the annual board of director compensation. The stock options were issued and are exercisable at $9.90 at any time from date of issuance and expire 5 years from the date of issuance.

 

On December 18, 2020, the Company issued stock options to purchase 691,600 shares of common stock as part of the annual board of director compensation. The stock options have a vesting period, where 25% of the stock options vest on the grant date, and the remaining 75% vest over a 3 year period, on the first, second, and third anniversary of the grant date. The stock options were issued and are exercisable at $13.91 at any time from date of issuance and expire 5 years from the date of issuance. The amortization for the quarter ended March 31, 2021 was $679,276. The remaining amortization over the next 5 years is $3,721,610.

 

On January 19, 2021, the Company issued stock option grants to purchase a total of 4,800 shares of common stock, granting 800 shares each to the Chief Operations Officer, the Chief Scientific Officer and to four of its key consultants as part of their annual compensation. The stock options were issued and are exercisable at $42.09 at any time from date of issuance and expire 5 years from the date of issuance.

 

-17-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

8. Commitments and Contingencies 

 

Office Lease 

On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.

Challenge to US Patent

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

 

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

 

This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country. 

 

Royalty Agreements

 

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

 

-18-

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

8. Commitments and Contingencies (continued) 

 

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally, the Company obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy).

 

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

 

9. Subsequent Events 

 

On April 19, 2021, the Company issued 724 shares of common stock pursuant to a cashless exercise of warrants to purchase 760 shares at an average exercise price of $1.88 per share.

 

On April 30, 2021, the Company issued 13,500 shares of common stock pursuant a cash exercise of warrants at $12.50 per share.

 

On April 27, 2021, the Company entered into a Purchase Agreement with NeurMedix, and Acuitas, which are related party affiliates, pursuant to which the Company has agreed to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration described below. The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease.

 

At the closing of the Transaction, BioVie will issue to NeurMedix 8,361,308 shares of the Company’s common stock and make a cash payment equal to the aggregate amount of NeurMedix’s direct and documented cash expenditures to advance certain clinical programs from March 1, 2021 through the closing, which cash payment is estimated to be approximately $3.0 million. Subject to the terms and conditions of the Purchase Agreement, following the closing, BioVie will also be obligated to deliver contingent consideration to NeurMedix (or its successor) consisting of (i) a cash payment of approximately $7.3 million, subject to a pivotal clinical trial for NE3107 meeting its primary endpoint(s) and BioVie having successfully raised at least $50 million in new capital, and (ii) shares of BioVie’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by the Company from NeurMedix, as more fully set forth in the Purchase Agreement.

 

On May 9, 2021, the Company, NeurMedix and Acuitas entered into Amendment No. 1 to the APA (the “Amendment” and the APA as so amended, the “Purchase Agreement”), pursuant to which the parties agreed, among other things, to modify the contingent stock consideration that BioVie may be obligated to deliver to NeurMedix (or its successor) pursuant to the Purchase Agreement. Previously, BioVie was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of BioVie’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by BioVie from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 89.9999% of BioVie’s issued and outstanding common stock. Pursuant to the Amendment, BioVie will be obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of up to 18.0 million shares of BioVie’s common stock, with 4.5 million shares issuable upon the achievement of each of the four milestones set forth in the Purchase Agreement, subject to a cap limiting the issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of BioVie’s issued and outstanding common stock.

 

The Transaction is expected to close twenty calendar days after a related definitive information statement on Schedule 14C is mailed to the Company’s stockholders and is anticipated to close in the second calendar quarter of 2021.

 

-19-

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. 

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. 

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc. 

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document. 

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales, expenses and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation. 

Management’s Discussion

 

BioVie Inc. is a clinical-stage company pursuing the discovery and development of innovative drug therapies to address severe unmet needs in chronic debilitating diseases. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

 

-20-

Comparison of the three months ended March 31, 2021 to the three months ended March 31, 2020

 

Net income (loss)

The net loss for the three months ended March 31, 2021 was approximately $3 million as compared to a net loss of $366,000 for the three months ended March 31, 2020. The increase in loss of approximately $2.6 million was primarily due an increase in operating expenses of $2.3 million, a change in fair value of derivative liabilities of approximately $367,000, and a decrease in interest expense of approximately $34,000.

Total operating expenses for the three months ended March 31, 2021 were approximately $3 million as compared to $699,000 for the three months ended March 31, 2020.  The net increase of approximately $2.3 was primarily consisted of increases in research and development expenses of $344,000 and selling, general and administrative expenses of $2 million related to stock-based compensation and due diligence services related to the Company’s purchase of NeurMedix’s assets. (See Note 9 Subsequent events in the accompanying condensed financial statements.)

Research and Development Expenses

Research and development expenses were approximately $697,000 for the three months ended March 31, 2021, a net increase of approximately $344,000, from $353,000 for the three months ended March 31, 2020. Research and development activities increased in preparation and launch of the Phase 2b clinical trials.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $2.2 million for the three months ended March 31, 2021 compared to $289,000 for the three months ended March 31, 2020. The net increase of approximately $1.9 million was primarily attributed to legal and consulting expenses totaling approximately $1 million for due diligence services in the acquisition of NeurMedix assets, and approximately $804,000 related to stock-based compensation for stock options granted to certain management and the Company’s key consultants and amortization for stock options granted to directors.

Comparison of the nine months ended March 31, 2021 to the nine months ended March 31, 2020

 

Net income (loss)

 

The net income for the nine months ended March 31, 2021 was $1.3 million as compared to a net income of $2.5 million for the nine months ended March 31, 2020. The decrease in net income of $1.2 million was due to a decrease in interest expense of $3 million related to the embedded derivative liability warrants offset by operating expenses increases totaling $4.3 million.

 

Total operating expenses for the nine months ended March 31, 2021 were approximately $6.5 million compared to $2.1 million for the nine months ended March 31, 2020.  The net increase of approximately $4.4 million was primarily consisted of increases in research and development expenses of $757,000 and selling, general and administrative expenses of $3.6 million attributed to stock-based compensation expenses for due diligence related to the purchase of the NeurMedix assets.

Research and Development Expenses

 

Research and development expenses were approximately $1.8 million for the nine months ended March 31, 2021, an increase of $757,000, from $1 million for the nine months ended March 31, 2020. Research and development activities increased in preparation and launch of Phase 2b clinical trials.

-21-

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were approximately $4.5 million for the nine months ended March 31, 2021, a net increase of approximately $3.6 million, from $941,000 for the nine months ended March 31, 2020. The net increase primarily consisted of stock-based compensation of $2.3 million related to stock options granted to the Board of Directors, management and certain key consultants to the Company and amortization for stock options granted to directors; and legal and consulting expenses totaling approximately $1 million for due diligence services in the acquisition of NeurMedix assets as described below.

 

Capital Resources and Liquidity

 

As of March 31, 2021, the Company had working capital of approximately $10 million and cash of $11.4 million and, stockholders’ equity was approximately $11.4 million, and its accumulated deficit was approximately $93.4 million. In addition, the Company has not generated any revenues and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

 

As described in Note 9 Subsequent Events in the accompany condensed interim financial statements, on April 27, 2021, the Company entered into an Asset Purchase Agreement which was amended by Amendment No. 1 to the Asset Purchase Agreement on May 9, 2021, (collectively “the Amended Asset Purchase Agreement”) with Neurmedix to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration of cash and common stock of the Company. At the close of the transaction, the Company will issue 8,361,308 shares of the Company’s common stock and make a cash payment equal to the aggregate amount of NeurMedix’s direct and documented cash expenditures to advance certain clinical programs from March 1, 2021 through the closing, which cash payment is estimated to be approximately $3.0 million. The cash requirements for expenses such as the due diligence, legal fees and the fairness opinion and including the $3 million cash consideration totals approximately $ 7.4 million and will be due at the close of the transaction, currently anticipated in the last quarter of our fiscal year. These expenditures will have a significant impact on the Company’s cash position and the funding of its future operations over the next 12 months, raising substantial doubt about its ability to meet its financial cash flow requirements. Subject to the terms and conditions of the Amended Asset Purchase Agreement following the closing, BioVie will also be obligated to deliver contingent consideration to NeurMedix (or its successor) consisting of (i) a cash payment of approximately $7.3 million, subject to a pivotal clinical trial for NE3107 meeting its primary endpoint(s) and BioVie having successfully raised at least $50 million in new capital, and (ii) contingent stock consideration to NeurMedix (or its successor) consisting of up to 18.0 million shares of BioVie’s common stock, with 4.5 million shares issuable upon the achievement of each of the four milestones set forth in the Purchase Agreement, subject to a cap limiting the issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of BioVie’s issued and outstanding common stock.

 

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of sufficient financing, we cannot assure that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.

 

Management intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.

 

Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The emergence of widespread health emergencies or pandemics of the coronavirus ("Covid-19"), may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability, including the duration and spread of the outbreak and restrictions and the impact of Covid-19 on the financial markets and the overall economy, all of which are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds may be materially adversely affected.

 

-22-

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets. 

Critical Accounting Policies and Estimates

 

For the nine-month period ended March 31, 2021, there were no significant changes to the Company’s critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2020.

New Accounting Pronouncements

 

The Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable

 

Item 4.  Controls and Procedures

 

We maintain “disclosure controls and procedures.” Such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Office and Chief Financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and procedures. The design of and disclosure controls and procedures also are based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act), that occurred during the quarter ended Mach 31, 2021 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

-23-

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

To our knowledge, neither the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

Item 1A. Risk Factors 

Not applicable to smaller reporting companies.

 

Item 2. Unregistered sales of equity securities

 

None

 

Item 3. Defaults Upon Senior Securities

 

None

 

Item 4.  Mine Safety Disclosures

 

None

 

Item 5.  Other Information

 

None 

 

-24-

Item 6. Exhibits

 

(a) Exhibit index

 

Exhibit 
31.1*   Certification of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*   Certification of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32.1**   Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document

 

* Filed herewith.
   
** Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

-25-

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioVie Inc.,

         
Signature   Titles   Date
     

 

/s/ Cuong V Do

________________

Cuong V Do

   Chairman and Chief Executive Officer (Principal Executive Officer)   May 10, 2021

 

 

 

 

/s/ Joanne Wendy Kim

________________

Joanne Wendy Kim

   Chief Financial Officer (Principal Financial and Accounting Officer)    May 10, 2021

 

-26-

 EX-31.1 2 bivi-20210331_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

     

I, Cuong V Do, certify that:
     
1. I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 10, 2021

                /s/ Cuong V Do
               
Cuong V Do
Chief Executive Officer
(Principal Executive Officer)
 
 EX-31.2 3 bivi-20210331_10qex31z2.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

     

I, Joanne Wendy Kim, certify that:
     
1. I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 10, 2021

                /s/ Joanne Wendy Kim
               

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

 
 EX-32.1 4 bivi-20210331_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

 

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cuong V Do, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: May 10, 2021

                /s/ Cuong V Do
                Cuong V Do
Chief Executive Officer
(Principal Executive Officer)

 

 
 EX-32.2 5 bivi-20210331_10qex32z2.htm EXHIBIT 32.2

Exhibit 32.2

 

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 10, 2021

                  /s/ Joanne Wendy Kim
                 

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

 
 EX-101.SCH 6 bivi-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Changes in Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Equity Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Equity Transactions (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Equity Transactions (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bivi-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bivi-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bivi-20210331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Derivative Instrument [Axis] Equity Option [Member] Warrant [Member] Related Party [Axis] Acuitas Group Holdings L L C [Member] Concentration Risk Benchmark [Axis] Derivative Liability Warrants [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Derivative Liability Conversion Option On Convertible Debenture [Member] Title of Individual [Axis] Director [Member] Stock Option 1 [Member] Stock Option 2 [Member] Stock Option 3 [Member] Stock Option 4 [Member] Stock Option 5 [Member] Stock Option 6 [Member] Stock Option 7 [Member] Stock Option 8 [Member] Stock Option 9 [Member] Stock Option 10 [Member] Stock Option 11 [Member] Stock Option 12 [Member] Stock Option 13 [Member] Stock Option 14 [Member] Stock Option 15 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Other assets Total current assets OTHER  ASSETS: Intangible assets, net Goodwill Total other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES: Accounts payable and accrued expenses Derivative liability - warrants Derivative liability - conversion option on convertible debenture Convertible debenture - related party, net of unearned discount of $0 and $462,864 and capitalized accrued interest of $0 and $48,407 at March 31, 2021 and June 30, 2020, respectively Total current liabilities Loan payable TOTAL LIABILITIES Commitments and contingencies (Note 8) STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2021 and June 30, 2020; 13,957,792 and 5,204,392 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively Additional paid in capital Accumulated deficit Total stockholders' equity (deficit) TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY (DEFICIT) Unearned Discount Capitalized Accured Interest Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] OPERATING EXPENSES: Amortization expense Research and development expenses Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER (INCOME) EXPENSE: Change in fair value of derivative liabilities Interest expense Interest income TOTAL OTHER (INCOME) EXPENSE, NET NET (LOSS) INCOME Deemed dividends - Related Party NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS NET (LOSS) INCOME PER COMMON SHARE - Basic - Diluted WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING - Basic - Diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net income Adjustments to reconcile net income to net cash used in operating activities: Amortization of intangible assets Stock based compensation Common shares issued for interest payment Common shares issued for service Interest expense from convertible debenture Changes in operating assets and liabilities Other assets Accounts payable and accrued expenses Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of common stock Proceeds from exercise of warrants Payment of convertible debenture - related party Proceeds from loan payable - related party Proceeds from convertible debenture - related party Net cash provided by financing activities Net  increase (decrease) in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for taxes SCHEDULE OF NON-CASH FINANCING ACTIVITIES: Deemed dividends - related party Stock warrants classified as derivative liability Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance Issuance of commitment shares Issuance of commitment shares, Shares Deemed dividend for purchase option - related party Net loss Ending Balance, Shares Ending Balance Issuance of shares for services Issuance of shares for services, Shares Issuance of shares for interest payment Issuance of shares for interest payment, Shares Net proceeds from issuance of common stock Net proceeds from issuance of common stock, Shares Redemption of warrants  - related party Redemption of warrants - related party, Shares Deemed dividend for purchase option - related party, Shares Cashless exercise of warrants Cashless exercise of options, Shares Proceeds from exercise of warrants, Shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Background Information Liquidity Liquidity Accounting Policies [Abstract] Significant Accounting Policies Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Related Party Transactions [Abstract] Related Party Transactions Fair Value Disclosures [Abstract] Fair Value Measurements Share-based Payment Arrangement [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation – Interim Financial Information Loan Pursuant to Paycheck Protection Program Net (loss) income per Common Share Recent accounting pronouncements number of outstanding stock options and warrants Significant Accounting Policies Summary of the intangible assets Intangible Assets Estimated future amortization expense Intangible Assets (Details 2) At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows: Fair Value Measurements activity for liabilities measured at fair value using unobservable inputs Fair Value Measurements (Details 2) activity relating to the Company’s stock options Equity Transactions weighted-average assumptions Equity Transactions (Details 2) summary of stock options outstanding and exercisable by exercise price Equity Transactions (Details 3) summarizes the warrants activity Equity Transactions (Details 4) Offsetting Assets [Table] Summary of Investment Holdings [Line Items] Shares, Outstanding Intellectual Property Less Accumulated Amortization Intellectual Property, Net Year ending June 30, 2021 (Remaining three months) 2022 2023 2024 2025 2026 Intellectual Property, Net Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Liability Beginning balance at July 1, 2020 Additions to level 3 liabilities Change in in fair value of level 3 liability Transfer in and/or out of Level 3 Balance at March 31, 2021 Share Price Exercise Price Term Volatility Rate Dividend Yield Risk-Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value, Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Remaining Average Contractual Term, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Weighted Remaining Average Contractual Term, Ending Balance Aggregate Intrinsic Value, Outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Expected life of options (In years) Expected volatility Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Weighted Average Contractual Life New Accounting Pronouncements or Change in Accounting Principle [Line Items] Warrant Outstanding, at the beginning of the period Weighted Average Exercise Price, at the beginning of the period Weighted Average Remaining Life, at the beginning of the period Warrant Outstanding, at the beginning of the period Weighted Average Exercise Price, at the beginning of the period Weighted Average Remaining Life, Granted Warrant Outstanding, at the beginning of the period Weighted Average Exercise Price, at the beginning of the period Warrant Exercised Weighted Average Exercise Price, Exercised Weighted Average Remaining Life, Exercised Warrant Exercised - Acuitas Weighted Average Exercise Price, Exercised - Acuitas Weighted Average Remaining Life, Exercised - Acuitas Warrant Outstanding, at the end of period Weighted Average Exercise Price, at the end of period Weighted Average Remaining Life, at the end of period Share-based Payment Arrangement, Noncash Expense Non-vested Options Granted Weighted Average Period for Recognition Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Exercisable period of Warrant [custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1] Subsequent Event [Table] Subsequent Event [Line Items] Loan Pursuant to Paycheck Protection Program [Policy Text Block] Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Gain (Loss) on Sale of Derivatives Interest Income, Other TotalOtherExpenseIncome Income (Loss) Attributable to Parent, before Tax Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable PaymentOfConvertibleDebentureRelatedParty Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stock Issued During Period, Value, New Issues LiquidityTextBlock DisclosureSignificantAccountingPoliciesDetailsAbstract DisclosureIntangibleAssetsDetailsAbstract DisclosureFairValueMeasurementsDetailsAbstract DisclosureEquityTransactionsDetailsAbstract Finite-Lived Intangible Assets, Accumulated Amortization Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share EX-101.PRE 10 bivi-20210331_pre.xml XBRL PRESENTATION FILE XML 11 bivi-20210331_10q_htm.xml IDEA: XBRL DOCUMENT 0001580149 2020-07-01 2021-03-31 0001580149 2021-05-07 0001580149 2021-03-31 0001580149 2020-06-30 0001580149 2021-01-01 2021-03-31 0001580149 2020-01-01 2020-03-31 0001580149 2019-07-01 2020-03-31 0001580149 2019-06-30 0001580149 2020-03-31 0001580149 us-gaap:CommonStockMember 2019-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001580149 us-gaap:RetainedEarningsMember 2019-06-30 0001580149 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001580149 2019-07-01 2019-09-30 0001580149 us-gaap:CommonStockMember 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-09-30 0001580149 2019-09-30 0001580149 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001580149 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001580149 2019-10-01 2019-12-31 0001580149 us-gaap:CommonStockMember 2019-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001580149 us-gaap:RetainedEarningsMember 2019-12-31 0001580149 2019-12-31 0001580149 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001580149 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001580149 us-gaap:CommonStockMember 2020-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001580149 us-gaap:RetainedEarningsMember 2020-03-31 0001580149 us-gaap:CommonStockMember 2020-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001580149 us-gaap:RetainedEarningsMember 2020-06-30 0001580149 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001580149 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001580149 2020-07-01 2020-09-30 0001580149 us-gaap:CommonStockMember 2020-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001580149 us-gaap:RetainedEarningsMember 2020-09-30 0001580149 2020-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001580149 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001580149 2020-09-01 2020-12-31 0001580149 us-gaap:CommonStockMember 2020-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001580149 us-gaap:RetainedEarningsMember 2020-12-31 0001580149 2020-12-31 0001580149 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001580149 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001580149 us-gaap:CommonStockMember 2021-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001580149 us-gaap:RetainedEarningsMember 2021-03-31 0001580149 us-gaap:StockOptionMember 2021-03-31 0001580149 us-gaap:StockOptionMember 2020-03-31 0001580149 us-gaap:WarrantMember 2021-03-31 0001580149 us-gaap:WarrantMember 2020-03-31 0001580149 bivi:AcuitasGroupHoldingsLLCMember 2020-09-22 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember 2021-03-31 0001580149 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001580149 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001580149 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember 2020-06-30 0001580149 us-gaap:FairValueInputsLevel1Member 2020-06-30 0001580149 us-gaap:FairValueInputsLevel2Member 2020-06-30 0001580149 us-gaap:FairValueInputsLevel3Member 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2021-03-31 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2021-03-31 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-09-24 2020-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-09-22 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2020-09-22 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-09-24 2020-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-09-22 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2020-07-01 2020-09-22 0001580149 us-gaap:StockOptionMember 2020-06-30 0001580149 us-gaap:StockOptionMember 2020-07-01 2021-03-31 0001580149 us-gaap:StockOptionMember 2019-07-01 2020-03-31 0001580149 srt:DirectorMember us-gaap:StockOptionMember 2020-07-01 2021-03-31 0001580149 bivi:StockOption1Member 2021-03-31 0001580149 bivi:StockOption1Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption2Member 2021-03-31 0001580149 bivi:StockOption2Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption3Member 2021-03-31 0001580149 bivi:StockOption3Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption4Member 2021-03-31 0001580149 bivi:StockOption4Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption5Member 2021-03-31 0001580149 bivi:StockOption5Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption6Member 2021-03-31 0001580149 bivi:StockOption6Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption7Member 2021-03-31 0001580149 bivi:StockOption7Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption8Member 2021-03-31 0001580149 bivi:StockOption8Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption9Member 2021-03-31 0001580149 bivi:StockOption9Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption10Member 2021-03-31 0001580149 bivi:StockOption10Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption11Member 2021-03-31 0001580149 bivi:StockOption11Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption12Member 2021-03-31 0001580149 bivi:StockOption12Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption13Member 2021-03-31 0001580149 bivi:StockOption13Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption14Member 2021-03-31 0001580149 bivi:StockOption14Member 2020-07-01 2021-03-31 0001580149 bivi:StockOption15Member 2021-03-31 0001580149 bivi:StockOption15Member 2020-07-01 2021-03-31 0001580149 us-gaap:WarrantMember 2020-06-30 0001580149 us-gaap:WarrantMember 2020-07-01 2021-03-31 0001580149 us-gaap:CommonStockMember 2020-07-27 2020-07-28 0001580149 2020-07-27 2020-07-28 0001580149 us-gaap:CommonStockMember 2021-01-26 2021-01-27 0001580149 2021-01-26 2021-01-27 0001580149 us-gaap:CommonStockMember 2021-03-22 2021-03-23 0001580149 2021-03-22 2021-03-23 0001580149 us-gaap:CommonStockMember 2021-03-22 2021-03-24 0001580149 2021-03-22 2021-03-24 0001580149 us-gaap:WarrantMember 2020-07-12 2020-07-13 0001580149 us-gaap:WarrantMember 2020-09-21 2020-09-22 0001580149 us-gaap:StockOptionMember 2020-09-29 2020-10-02 0001580149 us-gaap:StockOptionMember 2020-10-12 2020-10-13 0001580149 us-gaap:StockOptionMember 2020-12-17 2020-12-18 0001580149 us-gaap:StockOptionMember 2021-01-18 2021-01-19 0001580149 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-04-18 2021-04-19 0001580149 us-gaap:SubsequentEventMember 2021-04-18 2021-04-19 0001580149 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-04-29 2021-04-30 0001580149 us-gaap:SubsequentEventMember 2021-04-29 2021-04-30 iso4217:USD shares iso4217:USD shares pure 0001580149 false 2021 Q3 --06-30 10-Q true 2021-03-31 false 001-39015 BIOVIE INC. NV 46-2510769 2120 Colorado Avenue Suite 230 Santa Monica CA 90404 (310) 444-4300 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ Yes Yes Non-accelerated Filer true false false 13958516 11351258 37195 42855 375785 11394113 412980 1153194 1325226 345711 345711 1498905 1670937 12893018 2083917 1428434 1259206 16411504 5000800 0 462864 0 48407 848543 1428434 23520053 62500 62500 1490934 23582553 0.001 0.001 10000000 10000000 0 0 0 0 0.0001 0.0001 800000000 800000000 13957792 13957792 5204392 5204392 1395 520 104753666 19538742 -93352977 -41037898 11402084 -21498636 12893018 2083917 57344 57344 172032 172032 696657 353198 1759769 1003124 2247510 288711 4519830 940762 3001511 699253 6451631 2115918 -3001511 -699253 -6451631 -2115918 366550 8279919 8125328 33699 559455 3532234 8643 14408 233 -8643 -332851 -7734872 -4593327 -2992868 -366402 1283241 2477409 53598320 17099058 -2992868 -366402 -52315079 -14621649 -0.22 -0.07 -4.64 -3.02 -0.22 -0.07 -4.64 -3.02 13919933 5199003 11269212 4839802 13919933 5199003 11269212 4839802 1283241 2477409 172032 172032 2340533 24846 13487 39200 537275 3516537 8279919 8125328 332930 -243030 169228 856639 -3444680 -1268208 15628010 516551 1821818 432000 436000 500000 14758743 932000 11314063 -336208 37195 339923 11351258 3715 22180 2212 53598320 17099058 7530308 4058724 406 9392573 -7262072 2130907 1125000 112 10068638 10068750 -17099058 -17099058 -3821227 -3821227 5183724 518 19461211 -28182357 -8720628 11162 11162 6665038 6665038 5183724 518 19472373 -21517319 -2044428 13684 13684 11200 1 39199 39200 4422 13487 13487 -366402 -366402 5199346 519 19538743 -21883721 -2344459 5204392 520 19538742 -41037898 -21498636 1799980 180 15627830 15628010 1549750 155 13132230 13132385 5359832 536 53597784 -53598320 2210 7333916 7333916 13916164 1391 101896586 -87302302 14595675 1536929 1536929 -3057807 -3057807 13916164 1391 103433515 -90360109 13074797 803604 803604 304 41324 4 516547 516551 -2992868 -2992868 13957792 1395 104753666 -93352977 11402084 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zrVQX5Mzxpzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>1.</b></td> <td style="width: 97%"><b><span id="xdx_82F_zhGKXZd9GIe5">Background Information</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the “Company”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie completed a Phase 2a clinical trial of BIV201 in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute in Richmond, VA in 2019. The Company met with representatives of the Food and Drug Administration (“FDA”) in a Type C Guidance Meeting to discuss the study results and plan our next clinical study. Subsequently we requested a Type B Meeting and submitted an extensive pre-meeting information package. In April 2020, the FDA provided a written response that provided new guidance regarding primary and secondary endpoints, BIV201 dosing levels, quality of life measures and other key aspects of the clinical trial design. After further communications, the Company completed the clinical trial design protocol and was cleared to begin a Phase 2 clinical study. We activated the first trial sites in the first calendar quarter of 2021 and patient screening is now underway. The Phase 2 study results will be used to guide the design of a pivotal Phase 3 clinical trial. We have developed a patent-pending novel liquid formulation of BIV201 for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version of terlipressin.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company is applying for global patent coverage of a proprietary liquid formulation of terlipressin for use in the Phase 2 and Phase 3 clinical trials, which has been cleared by the FDA. This could eventually provide up to 20 years of patent protection in countries where the Company seeks patent issuance according to local patent laws.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the<span style="font-size: 8pt"> </span> rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 27, 2021, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with NeurMedix, Inc. (“NeurMedix”) and Acuitas Group Holdings, LLC (“Acuitas”), which are related party affiliates, pursuant to which the Company has agreed to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration of cash and shares of common stock. (collectively, the “Transaction”). The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease. See Note 9 - Subsequent Events.</p> <p id="xdx_802_ecustom--LiquidityTextBlock_z9O9p6XPw8vc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>2.</b></td> <td style="width: 97%"><b><span id="xdx_823_zyuEKr1hY9P6">Liquidity </span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt TimesNewRomanPS,serif; margin: 0; text-align: justify"><b>Liquidity and Going Concern</b></p> <p style="font: 10pt TimesNewRomanPS,serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2021, the Company had working capital of approximately $10 million and cash of $11.4 million and, stockholders’ equity was approximately $11.4 million, and its accumulated deficit was approximately $93.4 million. In addition, the Company has not generated any revenues and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. The emergence of widespread health emergencies or pandemics of the coronavirus ("Covid-19"), may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability, including the duration and spread of the outbreak and restrictions and the impact of Covid-19 on the financial markets and the overall economy, all of which are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds may be materially adversely affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zW9tYFowUaZj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>3.</b></td> <td style="width: 97%"><b><span id="xdx_82B_zZvzyKdJDJre">Significant Accounting Policies</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zD0THMMoNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i><span id="xdx_86B_zYByAbVXVZi8">Basis of Presentation – Interim Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2020 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2020 and 2019 in our Annual Report on form 10-K filed with Securities Exchange Commission (“SEC”) on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10K for the fiscal year ended June 30, 2020 filed with the SEC on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020.</p> <p id="xdx_856_zMgsf9Azphpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b><span style="font-size: 4pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>3.</b></td> <td style="width: 97%"><b>Significant Accounting Policies (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_84E_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zG6bIqauyTG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_863_zIsIqZMAbgZi">Loan Pursuant to Paycheck Protection Program</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company received $62,500 in loan proceeds pursuant to the Paycheck Protection Program (“PPP”), under the Coronavirus Aid Relief and Economic Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement by and between the Company and Lender. The Company applied for the loan in May 2020 and received funding for its maximum amount of $62,500 on May 21, 2020. The term of the loan is for 60 months and matures on the fifth-year anniversary from the date of funding. It bears interest at an annual rate of 1%. The PPP loan is subject to 100% forgiveness. The Company has filed the application for forgiveness, in February 2021 and is pending confirmation of forgiveness by the SBA. There can be no assurance that such forgiveness will occur. The Company is accounting for the loan as debt and if forgiveness is granted the Company will recognize a gain on extinguishment.</p> <p id="xdx_857_zNQIim69wRre" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i><span style="font-size: 4pt"> </span> </p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zOAHxIgsKXIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_869_zMkX9cEiWxBg">Net (loss) income per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the nine months ended March 31, 2021 and 2020, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liability creating a net loss available to common shareholders. For the three months ended March 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to net loss for the period.</p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSbJK58w5lM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the <span id="xdx_8B2_z7IKN5wMmuA1">number of outstanding stock options and warrants</span> as of March 31, 2021 and 2020:</p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zNe8GFaCT7Pl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBxlulo9bwT3" style="width: 12%; text-align: right">755,200</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--SharesOutstanding_iI_c20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zg1CHloGNPk9" style="width: 12%; text-align: right">68,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzpWlSm5AuS8" style="border-bottom: Black 1.5pt solid; text-align: right">173,021</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iI_c20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOJiWTlvGncb" style="border-bottom: Black 1.5pt solid; text-align: right">1,374,667</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iI_c20210331_zeVYO35o7sj1" style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">928,221</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--SharesOutstanding_iI_c20200331_zOJjS2Bc3kLf" style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,443,067</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zFxtfcld5O98" style="margin-top: 0; margin-bottom: 0"/> <p id="xdx_85C_zyzQA1ma0sye" style="font: 4pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOhYrHjVwRE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i><span id="xdx_862_zx2xQ6mqBH2l">Recent accounting pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. This ASU was adopted as of July 1, 2020. There has been no impact to its condensed financial statements and related disclosures.</p> <p id="xdx_853_z7vAdnHVEgek" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zD0THMMoNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i><span id="xdx_86B_zYByAbVXVZi8">Basis of Presentation – Interim Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2020 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2020 and 2019 in our Annual Report on form 10-K filed with Securities Exchange Commission (“SEC”) on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10K for the fiscal year ended June 30, 2020 filed with the SEC on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020.</p> <p id="xdx_84E_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zG6bIqauyTG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_863_zIsIqZMAbgZi">Loan Pursuant to Paycheck Protection Program</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company received $62,500 in loan proceeds pursuant to the Paycheck Protection Program (“PPP”), under the Coronavirus Aid Relief and Economic Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement by and between the Company and Lender. The Company applied for the loan in May 2020 and received funding for its maximum amount of $62,500 on May 21, 2020. The term of the loan is for 60 months and matures on the fifth-year anniversary from the date of funding. It bears interest at an annual rate of 1%. The PPP loan is subject to 100% forgiveness. The Company has filed the application for forgiveness, in February 2021 and is pending confirmation of forgiveness by the SBA. There can be no assurance that such forgiveness will occur. The Company is accounting for the loan as debt and if forgiveness is granted the Company will recognize a gain on extinguishment.</p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zOAHxIgsKXIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_869_zMkX9cEiWxBg">Net (loss) income per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the nine months ended March 31, 2021 and 2020, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liability creating a net loss available to common shareholders. For the three months ended March 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to net loss for the period.</p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSbJK58w5lM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the <span id="xdx_8B2_z7IKN5wMmuA1">number of outstanding stock options and warrants</span> as of March 31, 2021 and 2020:</p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zNe8GFaCT7Pl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBxlulo9bwT3" style="width: 12%; text-align: right">755,200</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--SharesOutstanding_iI_c20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zg1CHloGNPk9" style="width: 12%; text-align: right">68,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzpWlSm5AuS8" style="border-bottom: Black 1.5pt solid; text-align: right">173,021</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iI_c20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOJiWTlvGncb" style="border-bottom: Black 1.5pt solid; text-align: right">1,374,667</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iI_c20210331_zeVYO35o7sj1" style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">928,221</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--SharesOutstanding_iI_c20200331_zOJjS2Bc3kLf" style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,443,067</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zFxtfcld5O98" style="margin-top: 0; margin-bottom: 0"/> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zSbJK58w5lM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the <span id="xdx_8B2_z7IKN5wMmuA1">number of outstanding stock options and warrants</span> as of March 31, 2021 and 2020:</p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureSignificantAccountingPoliciesDetailsAbstract_zNe8GFaCT7Pl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBxlulo9bwT3" style="width: 12%; text-align: right">755,200</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--SharesOutstanding_iI_c20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zg1CHloGNPk9" style="width: 12%; text-align: right">68,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzpWlSm5AuS8" style="border-bottom: Black 1.5pt solid; text-align: right">173,021</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iI_c20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOJiWTlvGncb" style="border-bottom: Black 1.5pt solid; text-align: right">1,374,667</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iI_c20210331_zeVYO35o7sj1" style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">928,221</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td id="xdx_987_eus-gaap--SharesOutstanding_iI_c20200331_zOJjS2Bc3kLf" style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,443,067</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 755200 68400 173021 1374667 928221 1443067 <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOhYrHjVwRE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i><span id="xdx_862_zx2xQ6mqBH2l">Recent accounting pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. This ASU was adopted as of July 1, 2020. There has been no impact to its condensed financial statements and related disclosures.</p> <p id="xdx_803_eus-gaap--IntangibleAssetsDisclosureTextBlock_zZ00UkVyghq" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>4.</b></td> <td style="width: 97%"><b><span id="xdx_824_zgM7PQYucIAf">Intangible Assets</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of March 31, 2021 and June 30, 2020:</p> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zzAjtsyQJuSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; display: none"><span id="xdx_8B7_zWDQnH00ag7j">Summary of the intangible assets</span></p> <table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_zSifBxmF7qLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_499_20210331_zQH4HkIHqSIe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_49F_20200630_zDpx3DRZtS9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2020</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCz2t2_ziTmSMKlQNvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCz2t2_zINQCCKV05Ph" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,140,576</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(968,544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCz2t2_zAKNO3kU6r52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,153,194</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,325,226</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zQl4D1RHMEE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense for the three-month period ended March 31, 2021 and 2020 was $57,344 and $57,344 respectively. Amortization expense for the nine-month period ended March 31, 2021 and 2020 was $172,032 and $172,032 respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJXu3GEVcXy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B7_zwussJuR0ZVc">Estimated future amortization expense</span> is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zDVkO9078i5e" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td id="xdx_497_20210331_zz6UBEY8FIr4" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzvmc_zvg2xIcuJIn" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Year ending June 30, 2021 (Remaining three months) </td> <td style="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"> $                           57,344 </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maCz1vM_zfIJPBu1f5Uh" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2022</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maCz1vM_zyrTcoNHXJGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2023</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maCz1vM_zMDkvMS546Fh" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2024</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maCz1vM_zD5gSJFXwfai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2025</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_iI_maCz1vM_zeRY3UsgVefb" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2026</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            178,342 </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzvmc_zecT9CZOhWml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="display: none">Intellectual Property, Net</span></td> <td style="border-top: Black 1.5pt solid; white-space: nowrap; border-bottom: Black 4pt double; padding-right: 5.4pt; padding-left: 5.4pt"> $                      1,153,194 </td></tr> </table> <p id="xdx_8AC_zG5a0jL495y2" style="margin-top: 0; margin-bottom: 0"/> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zzAjtsyQJuSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; display: none"><span id="xdx_8B7_zWDQnH00ag7j">Summary of the intangible assets</span></p> <table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_zSifBxmF7qLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_499_20210331_zQH4HkIHqSIe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_49F_20200630_zDpx3DRZtS9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2020</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maCz2t2_ziTmSMKlQNvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCz2t2_zINQCCKV05Ph" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,140,576</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(968,544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCz2t2_zAKNO3kU6r52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">Intellectual Property, Net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,153,194</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,325,226</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 2293770000 2293770000 1140576000 968544000 1153194000 1325226000 <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJXu3GEVcXy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B7_zwussJuR0ZVc">Estimated future amortization expense</span> is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zDVkO9078i5e" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td id="xdx_497_20210331_zz6UBEY8FIr4" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_maFLIANzvmc_zvg2xIcuJIn" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Year ending June 30, 2021 (Remaining three months) </td> <td style="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"> $                           57,344 </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_maCz1vM_zfIJPBu1f5Uh" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2022</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_maCz1vM_zyrTcoNHXJGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2023</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_maCz1vM_zMDkvMS546Fh" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2024</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_maCz1vM_zD5gSJFXwfai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2025</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            229,377 </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_iI_maCz1vM_zeRY3UsgVefb" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2026</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">                            178,342 </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzvmc_zecT9CZOhWml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="display: none">Intellectual Property, Net</span></td> <td style="border-top: Black 1.5pt solid; white-space: nowrap; border-bottom: Black 4pt double; padding-right: 5.4pt; padding-left: 5.4pt"> $                      1,153,194 </td></tr> </table> 57344000 229377000 229377000 229377000 229377000 178342000 1153194000 <p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zk40LRgwVmm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>5.</b></td> <td style="width: 97%"><b><span id="xdx_828_zPhEApZRtlCi">Related Party Transactions</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Equity Transactions with Acuitas </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 22, 2020, concurrent with the closing of the Company’s Offering, approximately $1.8 million was paid to Acuitas satisfying all amounts owed on the Debenture due September 24, 2020 held by the Company’s controlling stockholder, Acuitas.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20200922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_zbMU4Uplc5c2">6,909,582</span> shares of Common Stock to Acuitas, representing (i) 5.4 million shares issuable pursuant to Acuitas’ rights under the Purchase Agreement dated July 3, 2018, as amended on June 24, 2019 and October 9, 2019; and the various extension letters as more fully described below; which resulted in a deemed dividend at the close of the public offering at price of $10 per share, consistent with the Company’s accounting policy; and (ii) the automatic exercise of 1.5 million warrants issued to Acuitas in connection with the Debenture financing at the par value of the Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2020, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September 22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which 328,250 warrants had been issued. In accordance with the Debenture agreements, as more fully described below; at September 22, 2020 upon the Company’s close of its public offering, al1 the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional 96,500 shares common stock issued to Acuitas.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following paragraphs summarize the background of those financings and arrangements which were settled and redeemed on September 22, 2020.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>5.</b></td> <td style="width: 97%"><b>Related Party Transactions (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of Preferred Stock automatically converted into 1 share of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20px">-</td> <td style="width: 7px"> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock; </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p></td></tr> <tr style="vertical-align: top"> <td>-</td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq; </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p></td></tr> <tr style="vertical-align: top"> <td>-</td> <td> </td> <td style="text-align: justify">Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b><span style="font-size: 4pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>5.</b></td> <td style="width: 97%"><b>Related Party Transactions (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Convertible Debenture Transaction with Acuitas</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s current reverse stock split or December 1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of 1,125,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the year ended June 30, 2020, accordingly. A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of the unearned discount for the three-month period ended March 31, 2021 and 2020 of $0 and $20,307, respectively, and for the nine months period ended March 31, 2021 and 2020 of $21,336 and $41,902, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company received draws under the Debenture that totaled approximately $1.3 million during the year ended June 30, 2020. The total interest expense related to the draws under the Debenture was approximately $99,000 for the year ended June 30, 2020. On April 1, 2020, the Company entered an amendment to modify the payment of accrued interest amounts under the original terms of the Debenture to capitalize all such amounts as would otherwise accrue on the Debenture. On January 4, 2020, payment of $13,487 accrued interest due was paid through the issuance of 4,422 shares of the Company’s common stock. Acuitas and the Company continue to discuss the need and timing for some or all the remaining draws under the Debenture Agreement. Subsequent to the initial $500,000 draw on September 24, 2019, the Company received draws that totaled $813,000 as July 13, 2020, and accordingly; the Company issued additional Bridge Warrants to purchase 203,250 shares of common stock to its controlling stockholder under the terms of the Bridge Financing. Accordingly, on April 16, 2020, the Company recorded the warrants to purchase 125,000 common stock related to the second $500,000 draw under the debenture as a derivative warrant liability as of June 30, 2020. The Company recorded the warrants related to the draws totaling $313,000 to purchase 78,250 common shares as derivative liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b><span style="font-size: 4pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>5.</b></td> <td style="width: 97%"><b>Related Party Transactions (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the 2019 Purchase Agreement, Acuitas agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">-</td> <td style="text-align: justify">The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">-</td> <td style="text-align: justify">Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">-</td> <td style="text-align: justify">The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto. </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 14, 2020, the Company, entered into a further extension of its letter agreements dated April 8, 2020, that furthered extended its letter agreement dated February 10, 2020 with Acuitas regarding Acuitas’ previous agreement to modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life of the Company’s intellectual property rights and commitment to purchase such securities upon the closing of the Offering and commitment to purchase such additional securities would remain effective until October 31, 2020, and accordingly Acuitas was entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company’s current bridge financing with Acuitas were to be made based with respect to the Company’s ongoing capital requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith. The letter agreement of July 14, 2020 also confirmed the understanding between the Company and Acuitas regarding certain amounts funded to BioVie that were intended as “partial draws” of credit available under the Debenture which, as of July 14, 2020 hereof aggregated $813,000 in aggregate principal amount in additional to amounts initial funded under the Debenture. Accordingly, such “partial draws” accrued additional principal as amounts otherwise funded pursuant to the original schedule of draws included in the Debenture (as modified by the letter agreement between BioVie and Acuitas dated April 1, 2020 regarding the capitalization of interest otherwise payable) and shall entitle Acuitas to receive a pro rata amount of Bridge Warrants.</p> 6909582 <p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zbGmFtz8J3j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>6.</b></td> <td style="width: 97%"><b><span id="xdx_825_z3Jn0W0gL0Ig">Fair Value Measurements</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 22, 2020, concurrent with the closing of the Offering; the warrants related to derivative liabilities were automatically exercised in full and the convertible Debenture was paid off in cash expiring the conversion option. The fair value of the derivative liabilities - warrants and derivative liability - conversion option on convertible Debenture prior to redemption at September 22, 2020 was $13.1 million, and the change in the fair value of $8.3 million from June 30, 2020 was recorded in the accompanying condensed Statements of Operations. At September 22, 2020, the derivative liabilities, both the warrants and expired conversion option totaling $ 13.1 million were then recorded as additional paid in capital upon automatic exercise of the warrants and payoff of the Debenture.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zQfMhzYaXNck" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_z3GheVYMU3Si" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><b>Fair Value Measurements at<br/>March 31, 2021</b></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center; padding-left: 5.4pt"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Level 1</b></td><td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Level 2</b></td><td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Level 3</b></td><td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Total</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left; padding-left: 5.4pt">Derivative liability - Warrants</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOsoIlzE4oq" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHWQMfoqyJ3h" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVMfZnr5gg34" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_zJkeTFSclL5b" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">—</span>  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD8N8xxHASGb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMTym8DAkS4g" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgnybf6tJ3yg" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_zddJBqulMBd3" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">—</span>  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">   Total derivatives</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9Wxkx1LY1rf" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCLSokd5icIa" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDnP6fQgdlvd" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iI_c20210331_zJzLmpwKA5Wd" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">—</span>  </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="15" style="font-weight: bold; text-align: center">Fair Value Measurements at</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Derivative liability - Warrants</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zY9FQ1HVFBW9" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_znpdVMVCrH74" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zek56OfHDf43" style="width: 10%; text-align: right">16,411,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_zD7C9gnm8Xxa" style="width: 10%; text-align: right">16,411,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJad4VuTYbU5" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zitcnkgnddJ1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmo03Z6czPw2" style="border-bottom: Black 1.5pt solid; text-align: right">5,000,800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_zMyBedFqEMo" style="border-bottom: Black 1.5pt solid; text-align: right">5,000,800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">   Total derivatives</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx6w9lYlw9Ec" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zXzlCbF6nhal" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iI_c20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAaKPjoB2tR1" style="border-bottom: Black 4pt double; text-align: right">21,412,304</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iI_c20200630_zL12G4vBv5Gh" style="border-bottom: Black 4pt double; text-align: right">21,412,304</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zH4Y2KgZKUtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z4cjCKIjuh1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents the <span id="xdx_8BC_zhwPdPBQtZNf">activity for liabilities measured at fair value using unobservable inputs</span> for the nine months ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_zqE0gVITys1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_49A_20200701__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhGoswJErrr7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities - Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_491_20200701__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFKJ75nyXmog" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option on Convertible Debenture</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_406_eus-gaap--DerivativeLiabilities_iS_zKW3YyDFazDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Beginning balance at July 1, 2020</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,411,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,000,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_zbR0e8BJaAXj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_zDMh1hn5SmRh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,054,121</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,225,798</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zsqXYbycdVM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,357,383</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,775,002</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DerivativeLiabilities_iE_zdq4ymdn9Hnc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Balance at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z6UOG1Npepq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 4pt"><br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>6.</b></td> <td style="width: 97%"><b>Fair Value Measurements (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Derivative liability – Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model. The valuation at June 30, 2020 used the following assumptions: stock price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zG1Ys3g7VJF7" title="Share Price">14</span>, exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0STbSDlZhB7" title="Exercise Price">4.00</span>, term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dt_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrFCTrYrTTcl" title="Term">5 year</span> expiring April 2025, volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXZgSaXg4rMg" title="Volatility Rate">76.61%</span>, dividend yield of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1vcRtRhLrLb" title="Dividend Yield">0%</span>, and risk-free interest rate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm8eCi1vrQt1" title="Risk-Free Interest Rate">0.29%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation at September 22, 2020 of the warrants associated with equity financing prior to their automatic exercise in full used were the following assumptions: stock price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIQ9ebdESoze">9.55</span>, exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFdXPVzucP3i">4.00</span>, term of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dt_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z60CI5gOme67">4 year</span> expiring September 2024, volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKn6NBNKwPgh">79.69%</span>, dividend yield of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zo8EP7A5xyN5">0%</span>, and risk-free interest rate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeDRaYI4OA3b">0.21%</span>. (See note 5 “Related Party Transactions”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Derivative liability – Conversion option in convertible debenture</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized a derivative liability for the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture; which may be convertible into shares of common stock at $4.00 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The valuation at June 30, 2020 used the following assumptions: stock price of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8S3H0Y42Glg">14</span>, conversion price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCJiyBO5TlGl">4.00</span>, term of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMIqrcxby319">0.25</span> year expiring September 2020, volatility of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zc0Mj9NC5wWe">62.47%</span>, dividend yield of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbK5yMALNOj6">0%</span>, and risk-free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20190924__20200630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8GbxXjlaoFl">0.16%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation at September 22, 2020 used the following assumptions: stock price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z85nMRIFroE3">9.55</span>, conversion price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOf8CAXhCis5">4.00</span>, term of 0.008 year expiring September 2020, volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMvMPs20cDKa">45.49%</span>, dividend yield of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhL7EOpoaWj8">0%</span>, and risk-free interest rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20200922__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWwE3NAraI1">0.01%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The related Debenture was paid off in cash on September 22, 2020, expiring the conversion option. (See note 5 “Related Party Transactions<i>”</i>)</p> <p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zQfMhzYaXNck" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_z3GheVYMU3Si" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><b>Fair Value Measurements at<br/>March 31, 2021</b></td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center; padding-left: 5.4pt"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Level 1</b></td><td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Level 2</b></td><td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Level 3</b></td><td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; text-align: center"><b>Total</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: left; padding-left: 5.4pt">Derivative liability - Warrants</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOsoIlzE4oq" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHWQMfoqyJ3h" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVMfZnr5gg34" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">—</span>  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_zJkeTFSclL5b" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">—</span>  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zD8N8xxHASGb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMTym8DAkS4g" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgnybf6tJ3yg" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_zddJBqulMBd3" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">—</span>  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">   Total derivatives</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9Wxkx1LY1rf" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCLSokd5icIa" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20210331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDnP6fQgdlvd" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iI_c20210331_zJzLmpwKA5Wd" style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">—</span>  </td></tr> </table> 16411504 16411504 5000800 5000800 21412304 21412304 <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z4cjCKIjuh1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents the <span id="xdx_8BC_zhwPdPBQtZNf">activity for liabilities measured at fair value using unobservable inputs</span> for the nine months ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_zqE0gVITys1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_49A_20200701__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhGoswJErrr7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities - Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_491_20200701__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFKJ75nyXmog" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option on Convertible Debenture</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr id="xdx_406_eus-gaap--DerivativeLiabilities_iS_zKW3YyDFazDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Beginning balance at July 1, 2020</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,411,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,000,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_zbR0e8BJaAXj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">—</span>  </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_zDMh1hn5SmRh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,054,121</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,225,798</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zsqXYbycdVM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,357,383</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,775,002</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DerivativeLiabilities_iE_zdq4ymdn9Hnc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Balance at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">—</span>  </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 16411504 5000800 -6054121 -2225798 -10357383 -2775002 14 4.00 P5Y 0.7661 0 0.0029 9.55 4.00 P4Y 0.7969 0 0.0021 14 4.00 P0Y3M 0.6247 0 0.0016 9.55 4.00 0.4549 0 0.0001 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zHOGBheNMcAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>7.</b></td> <td style="width: 97%"><b><span id="xdx_826_zggme7Nvoxkl">Equity Transactions</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Stock Options</i></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zHOo7YBp2Jjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the <span id="xdx_8B2_zp9M8RlffAgl">activity relating to the Company’s stock options</span> for the nine months ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureEquityTransactionsDetailsAbstract_zwMfvs6unJH6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2020</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZkRbeVmNKBb" style="width: 10%; text-align: right">60,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbX7RmNzaHH6" style="width: 10%; text-align: right">11.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zaSxvFetDBei" style="width: 10%; text-align: right">4.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztU5Ue7LNw19" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">352,600</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYHOqLjexRab" style="text-align: right">698,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2jCiLNJJuc4" style="text-align: right">14.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCsiYBOcHEx4" style="text-align: right" title="Weighted Remaining Average Contractual Term, Granted">4.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx71bI8bsax" style="text-align: right">954,239</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAMOC9OHgcO6" style="border-bottom: Black 1.5pt solid; text-align: right">(3,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbGw9r0bQXe" style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrFssb4WK01c" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrYDOgaeVDn" style="border-bottom: Black 4pt double; text-align: right">755,200</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxPo4n6R3Tih" style="border-bottom: Black 4pt double; text-align: right">13.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFFSr21Dl6ze" style="border-bottom: Black 4pt double; text-align: right" title="Weighted Remaining Average Contractual Term, Ending Balance">4.4</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeqMK3xZ5t3i" style="border-bottom: Black 4pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period">1,516,511</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztUwiMPO3xHc" style="border-bottom: Black 4pt double; text-align: right">236,500</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjKlcbBmHbK7" style="border-bottom: Black 4pt double; text-align: right">13.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEngd5hixKi" style="border-bottom: Black 4pt double; text-align: right">4.4</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwkDolBb27m4" style="border-bottom: Black 4pt double; text-align: right">1,516,511</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zwGzQSdudFff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_89F_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_zjnEkkHwj5Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following <span id="xdx_8B7_z8UHvAto2xWa">weighted-average assumptions</span> for the nine months ended March 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureEquityTransactionsDetails2Abstract_zJvTsnvpj1cf" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 48%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_493_20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA4KFYc9bDwb" style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>March 31, 2021</b></td> <td style="white-space: nowrap; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td id="xdx_499_20190701__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGfDhfrVppa" style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>March 31, 2020</b></td></tr> <tr id="xdx_40A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zRDLbOA9qKD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Expected life of options (In years)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">5</td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_zYDR9lAk1Ovi" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Expected volatility</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">77.05%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">73.74%</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_zzISs3hBrdP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Risk free interest rate</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.5%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.63%</td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_z1EX0nxgpIja" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Dividend Yield</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0%</td></tr> </table> <p id="xdx_8A4_zKhGj9R4yXC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company recorded stock-based compensation expense of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20210101__20210331_zmWnEKcNuCeh">803,604</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20200701__20210331_zjFwKpywNER5">2,340,533</span> for the three- and nine- month periods ended March 31, 2021, respectively, and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20200101__20200331_zuHYhYNZH3u7">13,684</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20190701__20200331_zoCN71Ns8NTj">24,846</span> for the three- and nine- month periods ended March 31, 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">As of March 31, 2021, unrecognized stock-based compensation cost was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zHbCtUKJSFcj" title="Non-vested Options Granted">3,721,620</span> which is expected to be recognized over a weighted-average period of approximately <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dt_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zK0GGNUfswO7" title="Weighted Average Period for Recognition">3 years</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>7.</b></td> <td style="width: 97%"><b>Equity Transactions (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_89E_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zobQxLZrifK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a <span id="xdx_8BA_zPvLPvQfw0qi">summary of stock options outstanding and exercisable by exercise price</span> as of March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureEquityTransactionsDetails3Abstract_zY7GRE2h2Us5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"> <tr style="vertical-align: bottom"> <td/> <td colspan="3" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zANgXF4Tu5W9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zN3EMcz45Myi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Contract Life</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_z7LQpLlyL43f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable</td></tr> <tr id="xdx_410_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zEGXxfcOVXQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 0%"/> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">7,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zMJ3VJH44vf4" style="width: 20%; text-align: right" title="Weighted Average Contractual Life">3.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">7,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_419_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zcZ14o5icij5" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zo4aHVif5s19" style="text-align: right">2.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zyttUtWKVoBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zlc0RgoshoPh" style="text-align: right">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_414_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zztQ20jtfWcc" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zndYOU8rOra8" style="text-align: right">4.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_z5L46E6oja8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">8.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zeAt7wEH4QNf" style="text-align: right">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zBYvfFfSWlh9" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">9.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_z5LQwD6zHD0j" style="text-align: right">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zyMrLsCFVaUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">9.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_z3Ke8o3bEHql" style="text-align: right">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_z1AcBSKTpRqg" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_z8zgOLvh1Ns8" style="text-align: right">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4e6F8bugKG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">13.91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">691,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z8S43NeDrd6" style="text-align: right">4.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,900</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zJCOkLxN6Zo8" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">25.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zOAtgJtZxXtb" style="text-align: right">1.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zE6xI3LIhp3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">26.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zL9Y7xl3PR82" style="text-align: right">1.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zKzEHku8scm8" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zIvJOD4ZmQr8" style="text-align: right">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zXIcRXvUcjb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">28.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zHa1fnFAXDvl" style="text-align: right">1.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zkkvBXmXW4Ej" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">31.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zEBtg8UNShGh" style="text-align: right">0.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zmkPBQud1klh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">42.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zcr51Grv7oIa" style="text-align: right">4.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zQgO4Sar7RDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zQrF6gX5lpca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table <span id="xdx_8B3_zRHK1vhSzP14">summarizes the warrants activity</span> during the nine months ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureEquityTransactionsDetails4Abstract_z4UVyrtg8Vx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2020</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQgWuQGkTCui" style="width: 10%; text-align: right" title="Warrant Outstanding, at the beginning of the period">1,374,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP6xOJBAgSs1" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, at the beginning of the period">7.72</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVoaWmhW5AM6" style="width: 10%; text-align: right" title="Weighted Average Remaining Life, at the beginning of the period">4.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj4XFGZxOMIb" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">13,799,331</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXCI1xyOMrP7" style="text-align: right" title="Warrant Outstanding, at the beginning of the period">293,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEDjNfIFgsM3" style="text-align: right" title="Weighted Average Exercise Price, at the beginning of the period">6.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsLUuwB8ZEt5" style="text-align: right" title="Weighted Average Remaining Life, Granted">5.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQC6D5pdCyMe" style="text-align: right" title="Warrant Outstanding, at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl0763">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu7SR6Lafdwi" style="text-align: right" title="Weighted Average Exercise Price, at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl0765">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted Average Remaining Life, at the beginning of the period">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease1_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z32fJZL7xAr9" style="text-align: right" title="Warrant Exercised">(41,644</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQEZwpMlyfta" style="text-align: right" title="Weighted Average Exercise Price, Exercised">12.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms4_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDTd6MJ93g5" style="text-align: right" title="Weighted Average Remaining Life, Exercised">4.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Exercised - Acuitas</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrUnIBKOwNlg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant Exercised - Acuitas">(1,453,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxl0skXs716f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised - Acuitas">4.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms5_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuz22l65PwW5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, Exercised - Acuitas">4.0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at March 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRFfNNYeEARe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant Outstanding, at the end of period">173,021</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6JCPtlwCTga" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, at the end of period">10.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO7zHkFhoDmj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, at the end of period">3.4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKlUBvRa4XG8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period">2,203,264</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zqW1aDK425z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,815 expire in fiscal year ending June 30, 2023, 110,140 expire in fiscal year ending June 30, 2025 and 48,675 expire in fiscal year ending June 30, 2026.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>7.</b></td> <td style="width: 97%"><b>Equity Transactions (continued)</b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Issuance of common stock through exercise of Stock Options and Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 28, 2020, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200727__20200728__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ5c25K7acj8">2,210</span> shares of common stock pursuant to a cashless exercise of stock options to purchase <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200727__20200728_zPkUUsksSDd6">3,200</span> shares at an average exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200727__20200728_zP8I3lKX3tWa">4.76</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 27, 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210126__20210127__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPE5UVNpc8U">304</span> shares of common stock pursuant to a cashless exercise of warrants to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210126__20210127_z5hi1b3dCzK9">320</span> shares at an average exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210126__20210127_zDIK9enCUdJ8">1.88</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 23, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210322__20210323__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWaLDKpfEvD7">27,000</span> shares of common stock pursuant to a cash exercise of warrants to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210322__20210323_zwlJ8HDYYnbd">27,000</span> shares at an average exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210322__20210323_zl1VUbKM15ea">12.50</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 24, 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210322__20210324__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuBIeHDIKvRe">14,324</span> shares of common stock pursuant to a cash exercise of warrants to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210322__20210324_zrjTP0oqns6k">14,324</span> shares at an average exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210322__20210324_zsafsqfULIq2">12.50</span> per share.</p> <p style="font: 10pt/105% Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Issuance of warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 13, 2020, the Company issued Warrants to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200712__20200713__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcDpJO4bumg7">203,250</span> shares of common stock to its controlling stockholder under the terms of the Bridge Financing. The warrants were exercisable at an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20200712__20200713__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZkkvSELI9V5">4</span> at any time from the date of issuance until <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dt_c20200712__20200713__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYxJ60GXyeii" title="Exercisable period of Warrant">5 years</span> from the date of issuance. (See Note 5 Related Party Transactions.)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On September 22, 2020, the Company issued warrants to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200921__20200922__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXdYAkbCvS95">89,998</span> shares of common stock to the underwriters of the Offering in connection with the close of the Offering of registered Common Stock The warrants are exercisable at an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20200921__20200922__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwQphj67hYx4">12.50</span> at any time from date of issuance until <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dt_c20200921__20200922__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbo6XVc83sVd">5 years</span> from the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Issuance of stock options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2020, the Company issued stock options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200929__20201002__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYxbcJR6eRq">800</span> shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200929__20201002__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdzwRTdwXo87">9.54</span> at any time from date of issuance and expire <span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dt_c20200929__20201002__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ITS6uye8Y4">5 years</span> from the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 13, 2020, the Company issued stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201012__20201013__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zG6lifFsTs95">800</span> shares of common stock as part of the annual board of director compensation. The stock options were issued and are exercisable at $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201012__20201013__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJHCptw2und6">9.90</span> at any time from date of issuance and expire <span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dt_c20201012__20201013__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOaKDvwPyBQl">5 years</span> from the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 18, 2020, the Company issued stock options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201217__20201218__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAmhDiHAmA4g">691,600</span> shares of common stock as part of the annual board of director compensation. The stock options have a vesting period, where 25% of the stock options vest on the grant date, and the remaining 75% vest over a 3 year period, on the first, second, and third anniversary of the grant date. The stock options were issued and are exercisable at $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201217__20201218__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zy0zB3R2axxl">13.91</span> at any time from date of issuance and expire <span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dt_c20201217__20201218__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5kNjBMkJff5">5 years</span> from the date of issuance. The amortization for the quarter ended March 31, 2021 was $679,276. The remaining amortization over the next 5 years is $3,721,610.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 19, 2021, the Company issued stock option grants to purchase a total of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210118__20210119__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2Hims6BDQ2l">4,800</span> shares of common stock, granting 800 shares each to the Chief Operations Officer, the Chief Scientific Officer and to four of its key consultants as part of their annual compensation. The stock options were issued and are exercisable at $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210118__20210119__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWpuYQK6RGck">42.09</span> at any time from date of issuance and expire <span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dt_c20210118__20210119__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMQqcd9EwJ3g">5 years</span> from the date of issuance.</p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zHOo7YBp2Jjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the <span id="xdx_8B2_zp9M8RlffAgl">activity relating to the Company’s stock options</span> for the nine months ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureEquityTransactionsDetailsAbstract_zwMfvs6unJH6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2020</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZkRbeVmNKBb" style="width: 10%; text-align: right">60,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbX7RmNzaHH6" style="width: 10%; text-align: right">11.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zaSxvFetDBei" style="width: 10%; text-align: right">4.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztU5Ue7LNw19" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">352,600</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYHOqLjexRab" style="text-align: right">698,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2jCiLNJJuc4" style="text-align: right">14.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCsiYBOcHEx4" style="text-align: right" title="Weighted Remaining Average Contractual Term, Granted">4.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx71bI8bsax" style="text-align: right">954,239</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAMOC9OHgcO6" style="border-bottom: Black 1.5pt solid; text-align: right">(3,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbGw9r0bQXe" style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrFssb4WK01c" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">—</span>  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zrYDOgaeVDn" style="border-bottom: Black 4pt double; text-align: right">755,200</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxPo4n6R3Tih" style="border-bottom: Black 4pt double; text-align: right">13.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFFSr21Dl6ze" style="border-bottom: Black 4pt double; text-align: right" title="Weighted Remaining Average Contractual Term, Ending Balance">4.4</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeqMK3xZ5t3i" style="border-bottom: Black 4pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period">1,516,511</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at March 31, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztUwiMPO3xHc" style="border-bottom: Black 4pt double; text-align: right">236,500</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjKlcbBmHbK7" style="border-bottom: Black 4pt double; text-align: right">13.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbEngd5hixKi" style="border-bottom: Black 4pt double; text-align: right">4.4</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwkDolBb27m4" style="border-bottom: Black 4pt double; text-align: right">1,516,511</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 60400 11.06 P4Y2M12D 352600 698000 14.63 P4Y8M12D 954239 3200 4.76 755200 13.85 P4Y4M24D 1516511 236500 13.85 P4Y4M24D 1516511 <p id="xdx_89F_ecustom--FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock_zjnEkkHwj5Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following <span id="xdx_8B7_z8UHvAto2xWa">weighted-average assumptions</span> for the nine months ended March 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureEquityTransactionsDetails2Abstract_zJvTsnvpj1cf" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 48%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_493_20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA4KFYc9bDwb" style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>March 31, 2021</b></td> <td style="white-space: nowrap; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td id="xdx_499_20190701__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIGfDhfrVppa" style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>March 31, 2020</b></td></tr> <tr id="xdx_40A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zRDLbOA9qKD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Expected life of options (In years)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">5</td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_zYDR9lAk1Ovi" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Expected volatility</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">77.05%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">73.74%</td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_zzISs3hBrdP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Risk free interest rate</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.5%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.63%</td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_z1EX0nxgpIja" style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Dividend Yield</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0%</td></tr> </table> P5Y P5Y 0.7705 0.7374 0.005 0.0163 0 0 803604 2340533 13684 24846 3721620 P3Y <p id="xdx_89E_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zobQxLZrifK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a <span id="xdx_8BA_zPvLPvQfw0qi">summary of stock options outstanding and exercisable by exercise price</span> as of March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureEquityTransactionsDetails3Abstract_zY7GRE2h2Us5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"> <tr style="vertical-align: bottom"> <td/> <td colspan="3" id="xdx_482_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_zANgXF4Tu5W9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zN3EMcz45Myi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Contract Life</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" id="xdx_481_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_z7LQpLlyL43f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable</td></tr> <tr id="xdx_410_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zEGXxfcOVXQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 0%"/> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">7,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption1Member_zMJ3VJH44vf4" style="width: 20%; text-align: right" title="Weighted Average Contractual Life">3.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">7,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_419_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zcZ14o5icij5" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption2Member_zo4aHVif5s19" style="text-align: right">2.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zyttUtWKVoBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption3Member_zlc0RgoshoPh" style="text-align: right">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_414_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zztQ20jtfWcc" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption4Member_zndYOU8rOra8" style="text-align: right">4.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_z5L46E6oja8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">8.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption5Member_zeAt7wEH4QNf" style="text-align: right">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_zBYvfFfSWlh9" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">9.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption6Member_z5LQwD6zHD0j" style="text-align: right">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_zyMrLsCFVaUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">9.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption7Member_z3Ke8o3bEHql" style="text-align: right">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_z1AcBSKTpRqg" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption8Member_z8zgOLvh1Ns8" style="text-align: right">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z4e6F8bugKG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">13.91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">691,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption9Member_z8S43NeDrd6" style="text-align: right">4.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,900</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zJCOkLxN6Zo8" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">25.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption10Member_zOAtgJtZxXtb" style="text-align: right">1.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zE6xI3LIhp3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">26.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption11Member_zL9Y7xl3PR82" style="text-align: right">1.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_419_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zKzEHku8scm8" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption12Member_zIvJOD4ZmQr8" style="text-align: right">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zXIcRXvUcjb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">28.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption13Member_zHa1fnFAXDvl" style="text-align: right">1.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zkkvBXmXW4Ej" style="vertical-align: bottom; background-color: White"> <td/> <td style="text-align: left">$</td><td style="text-align: right">31.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption14Member_zEBtg8UNShGh" style="text-align: right">0.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zmkPBQud1klh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td/> <td style="text-align: left">$</td><td style="text-align: right">42.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20210331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOption15Member_zcr51Grv7oIa" style="text-align: right">4.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,800</td><td style="text-align: left"> </td></tr> </table> 2.80 7200 P3Y9M18D 7200 3.75 4800 P2Y9M18D 4800 6.25 1600 P2Y7M6D 1600 7.50 25600 P4Y10M24D 25600 8.75 1600 P3Y 1600 9.54 800 P4Y6M 800 9.90 800 P4Y6M 800 12.50 4000 P1Y9M18D 4000 13.91 691600 P4Y8M12D 172900 25.00 1600 P1Y6M 1600 26.25 4400 P1Y1M6D 4400 27.50 800 P1Y 800 28.75 1600 P1Y4M24D 1600 31.25 4000 P0Y7M6D 4000 42.09 4800 P4Y9M18D 4800 <p id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zQrF6gX5lpca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table <span id="xdx_8B3_zRHK1vhSzP14">summarizes the warrants activity</span> during the nine months ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureEquityTransactionsDetails4Abstract_z4UVyrtg8Vx4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2020</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQgWuQGkTCui" style="width: 10%; text-align: right" title="Warrant Outstanding, at the beginning of the period">1,374,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP6xOJBAgSs1" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, at the beginning of the period">7.72</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVoaWmhW5AM6" style="width: 10%; text-align: right" title="Weighted Average Remaining Life, at the beginning of the period">4.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj4XFGZxOMIb" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">13,799,331</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXCI1xyOMrP7" style="text-align: right" title="Warrant Outstanding, at the beginning of the period">293,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEDjNfIFgsM3" style="text-align: right" title="Weighted Average Exercise Price, at the beginning of the period">6.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsLUuwB8ZEt5" style="text-align: right" title="Weighted Average Remaining Life, Granted">5.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQC6D5pdCyMe" style="text-align: right" title="Warrant Outstanding, at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl0763">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu7SR6Lafdwi" style="text-align: right" title="Weighted Average Exercise Price, at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl0765">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted Average Remaining Life, at the beginning of the period">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease1_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z32fJZL7xAr9" style="text-align: right" title="Warrant Exercised">(41,644</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQEZwpMlyfta" style="text-align: right" title="Weighted Average Exercise Price, Exercised">12.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms4_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSDTd6MJ93g5" style="text-align: right" title="Weighted Average Remaining Life, Exercised">4.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Exercised - Acuitas</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrUnIBKOwNlg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant Exercised - Acuitas">(1,453,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxl0skXs716f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised - Acuitas">4.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms5_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuz22l65PwW5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, Exercised - Acuitas">4.0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—  </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at March 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRFfNNYeEARe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant Outstanding, at the end of period">173,021</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6JCPtlwCTga" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, at the end of period">10.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_dtY_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO7zHkFhoDmj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Remaining Life, at the end of period">3.4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200701__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKlUBvRa4XG8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period">2,203,264</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 1374667 7.72 P4Y2M12D 13799331 293248 6.61 P5Y -41644 12.40 P4Y -1453250 4.00 P4Y 173021 10.49 P3Y4M24D 2203264 2210 3200 4.76 304 320 1.88 27000 27000 12.50 14324 14324 12.50 203250 4 P5Y 89998 12.50 P5Y 800 9.54 P5Y 800 9.90 P5Y 691600 13.91 P5Y 4800 42.09 P5Y <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_ziaUTs52Frb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><b>8.</b></td> <td style="width: 95%"><b><span id="xdx_82A_zEl4tIK41g2a">Commitments and Contingencies</span></b> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Office Lease </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Challenge to US Patent</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the <i>inter partes</i> review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Royalty Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Notes to Condensed Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Nine Months Ended March 31, 2021 and 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><b>8.</b></td> <td style="width: 95%"><b>Commitments and Contingencies (continued)</b> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally, the Company obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.</p> <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zGJs8rul56S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"><b>9.</b></td> <td style="width: 97%"><b><span id="xdx_824_zee4yiwhueK3">Subsequent Events</span></b> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 19, 2021, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210418__20210419__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlWemRIwIpM8">724</span> shares of common stock pursuant to a cashless exercise of warrants to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210418__20210419__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zI7OfO6QqJK4">760</span> shares at an average exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210418__20210419__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYOxySwZPMHa">1.88</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210429__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znWK8FgzEz68">13,500</span> shares of common stock pursuant a cash exercise of warrants at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210429__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzevkkY8dVN8">12.50</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 27, 2021, the Company entered into a Purchase Agreement with NeurMedix, and Acuitas, which are related party affiliates, pursuant to which the Company has agreed to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration described below. The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the closing of the Transaction, BioVie will issue to NeurMedix 8,361,308 shares of the Company’s common stock and make a cash payment equal to the aggregate amount of NeurMedix’s direct and documented cash expenditures to advance certain clinical programs from March 1, 2021 through the closing, which cash payment is estimated to be approximately $3.0 million. Subject to the terms and conditions of the Purchase Agreement, following the closing, BioVie will also be obligated to deliver contingent consideration to NeurMedix (or its successor) consisting of (i) a cash payment of approximately $7.3 million, subject to a pivotal clinical trial for NE3107 meeting its primary endpoint(s) and BioVie having successfully raised at least $50 million in new capital, and (ii) shares of BioVie’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by the Company from NeurMedix, as more fully set forth in the Purchase Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">On May 9, 2021, the Company, NeurMedix and Acuitas entered into Amendment No. 1 to the APA (the “Amendment” and the APA as so amended, the “Purchase Agreement”), pursuant to which the parties agreed, among other things, to modify the contingent stock consideration that BioVie may be obligated to deliver to NeurMedix (or its successor) pursuant to the Purchase Agreement. Previously, BioVie was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of BioVie’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by BioVie from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 89.9999% of BioVie’s issued and outstanding common stock. Pursuant to the Amendment, BioVie will be obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of up to 18.0 million shares of BioVie’s common stock, with 4.5 million shares issuable upon the achievement of each of the four milestones set forth in the Purchase Agreement, subject to a cap limiting the issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of BioVie’s issued and outstanding common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Transaction is expected to close twenty calendar days after a related definitive information statement on Schedule 14C is mailed to the Company’s stockholders and is anticipated to close in the second calendar quarter of 2021.</p> 724 760 1.88 13500 12.50 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover - shares
 9 Months Ended
Mar. 31, 2021
May 07, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --06-30  
Entity File Number 001-39015  
Entity Registrant Name BIOVIE INC.  
Entity Central Index Key 0001580149  
Entity Tax Identification Number 46-2510769  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 2120 Colorado Avenue Suite 230  
Entity Address, City or Town Santa Monica  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 90404  
City Area Code (310)  
Local Phone Number 444-4300  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share  
Trading Symbol BIVI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   13,958,516
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2021
Jun. 30, 2020
CURRENT ASSETS:    
Cash $ 11,351,258 $ 37,195
Other assets 42,855 375,785
Total current assets 11,394,113 412,980
OTHER  ASSETS:    
Intangible assets, net 1,153,194 1,325,226
Goodwill 345,711 345,711
Total other assets 1,498,905 1,670,937
TOTAL ASSETS 12,893,018 2,083,917
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 1,428,434 1,259,206
Derivative liability - warrants 16,411,504
Derivative liability - conversion option on convertible debenture 5,000,800
Convertible debenture - related party, net of unearned discount of $0 and $462,864 and capitalized accrued interest of $0 and $48,407 at March 31, 2021 and June 30, 2020, respectively 848,543
Total current liabilities 1,428,434 23,520,053
Loan payable 62,500 62,500
TOTAL LIABILITIES 1,490,934 23,582,553
STOCKHOLDERS' EQUITY (DEFICIT)    
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2021 and June 30, 2020; 13,957,792 and 5,204,392 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively 1,395 520
Additional paid in capital 104,753,666 19,538,742
Accumulated deficit (93,352,977) (41,037,898)
Total stockholders' equity (deficit) 11,402,084 (21,498,636)
TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY (DEFICIT) $ 12,893,018 $ 2,083,917
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Mar. 31, 2021
Jun. 30, 2020
Statement of Financial Position [Abstract]    
Unearned Discount $ 0 $ 462,864
Capitalized Accured Interest $ 0 $ 48,407
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 800,000,000 800,000,000
Common Stock, Shares, Issued 13,957,792 5,204,392
Common Stock, Shares, Outstanding 13,957,792 5,204,392
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
OPERATING EXPENSES:        
Amortization expense $ 57,344 $ 57,344 $ 172,032 $ 172,032
Research and development expenses 696,657 353,198 1,759,769 1,003,124
Selling, general and administrative expenses 2,247,510 288,711 4,519,830 940,762
TOTAL OPERATING EXPENSES 3,001,511 699,253 6,451,631 2,115,918
LOSS FROM OPERATIONS (3,001,511) (699,253) (6,451,631) (2,115,918)
OTHER (INCOME) EXPENSE:        
Change in fair value of derivative liabilities (366,550) (8,279,919) (8,125,328)
Interest expense 33,699 559,455 3,532,234
Interest income (8,643) (14,408) (233)
TOTAL OTHER (INCOME) EXPENSE, NET (8,643) (332,851) (7,734,872) (4,593,327)
NET (LOSS) INCOME (2,992,868) (366,402) 1,283,241 2,477,409
Deemed dividends - Related Party 53,598,320 17,099,058
NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (2,992,868) $ (366,402) $ (52,315,079) $ (14,621,649)
NET (LOSS) INCOME PER COMMON SHARE        
- Basic $ (0.22) $ (0.07) $ (4.64) $ (3.02)
- Diluted $ (0.22) $ (0.07) $ (4.64) $ (3.02)
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING        
- Basic 13,919,933 5,199,003 11,269,212 4,839,802
- Diluted 13,919,933 5,199,003 11,269,212 4,839,802
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 1,283,241 $ 2,477,409
Adjustments to reconcile net income to net cash used in operating activities:    
Amortization of intangible assets 172,032 172,032
Stock based compensation 2,340,533 24,846
Common shares issued for interest payment 13,487
Common shares issued for service 39,200
Interest expense from convertible debenture 537,275 3,516,537
Change in fair value of derivative liabilities (8,279,919) (8,125,328)
Changes in operating assets and liabilities    
Other assets 332,930 (243,030)
Accounts payable and accrued expenses 169,228 856,639
Net cash used in operating activities (3,444,680) (1,268,208)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from issuance of common stock 15,628,010
Proceeds from exercise of warrants 516,551
Payment of convertible debenture - related party (1,821,818)
Proceeds from loan payable - related party 432,000
Proceeds from convertible debenture - related party 436,000 500,000
Net cash provided by financing activities 14,758,743 932,000
Net  increase (decrease) in cash 11,314,063 (336,208)
Cash, beginning of period 37,195 339,923
Cash, end of period 11,351,258 3,715
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest 22,180 2,212
Cash paid for taxes
SCHEDULE OF NON-CASH FINANCING ACTIVITIES:    
Deemed dividends - related party 53,598,320 17,099,058
Stock warrants classified as derivative liability $ 7,530,308
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Statements of Changes in Stockholders' (Deficit) Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning Balance, Shares at Jun. 30, 2019 4,058,724      
Beginning Balance at Jun. 30, 2019 $ 406 $ 9,392,573 $ (7,262,072) $ 2,130,907
Issuance of commitment shares $ 112 10,068,638 10,068,750
Issuance of commitment shares, Shares 1,125,000      
Deemed dividend for purchase option - related party (17,099,058) (17,099,058)
Net loss (3,821,227) (3,821,227)
Ending Balance, Shares at Sep. 30, 2019 5,183,724      
Ending Balance at Sep. 30, 2019 $ 518 19,461,211 (28,182,357) (8,720,628)
Beginning Balance, Shares at Jun. 30, 2019 4,058,724      
Beginning Balance at Jun. 30, 2019 $ 406 9,392,573 (7,262,072) 2,130,907
Net loss       $ 2,477,409
Ending Balance, Shares at Mar. 31, 2020       1,443,067
Ending Balance at Mar. 31, 2020 $ 519 19,538,743 (21,883,721) $ (2,344,459)
Stock based compensation       24,846
Issuance of shares for services       39,200
Issuance of shares for interest payment       13,487
Proceeds from exercise of warrants      
Beginning Balance, Shares at Sep. 30, 2019 5,183,724      
Beginning Balance at Sep. 30, 2019 $ 518 19,461,211 (28,182,357) (8,720,628)
Net loss   6,665,038 6,665,038
Ending Balance, Shares at Dec. 31, 2019 5,199,346      
Ending Balance at Dec. 31, 2019 $ 518 19,472,373 (21,517,319) (2,044,428)
Stock based compensation   11,162 11,162
Net loss (366,402) $ (366,402)
Ending Balance, Shares at Mar. 31, 2020       1,443,067
Ending Balance at Mar. 31, 2020 519 19,538,743 (21,883,721) $ (2,344,459)
Stock based compensation 13,684 13,684
Issuance of shares for services $ 1 39,199 39,200
Issuance of shares for services, Shares 11,200      
Issuance of shares for interest payment 13,487 13,487
Issuance of shares for interest payment, Shares 4,422      
Beginning Balance, Shares at Jun. 30, 2020 5,204,392      
Beginning Balance at Jun. 30, 2020 $ 520 19,538,742 (41,037,898) (21,498,636)
Deemed dividend for purchase option - related party 536 53,597,784 (53,598,320)
Net loss 7,333,916 7,333,916
Ending Balance, Shares at Sep. 30, 2020 13,916,164      
Ending Balance at Sep. 30, 2020 $ 1,391 101,896,586 (87,302,302) 14,595,675
Net proceeds from issuance of common stock $ 180 15,627,830 15,628,010
Net proceeds from issuance of common stock, Shares 1,799,980      
Redemption of warrants  - related party $ 155 13,132,230 13,132,385
Redemption of warrants - related party, Shares 1,549,750      
Deemed dividend for purchase option - related party, Shares 5,359,832      
Cashless exercise of warrants
Cashless exercise of options, Shares 2,210      
Beginning Balance, Shares at Jun. 30, 2020 5,204,392      
Beginning Balance at Jun. 30, 2020 $ 520 19,538,742 (41,037,898) (21,498,636)
Net loss       $ 1,283,241
Ending Balance, Shares at Mar. 31, 2021       928,221
Ending Balance at Mar. 31, 2021 $ 1,395 104,753,666 (93,352,977) $ 11,402,084
Stock based compensation       2,340,533
Issuance of shares for services      
Issuance of shares for interest payment      
Proceeds from exercise of warrants       516,551
Beginning Balance, Shares at Sep. 30, 2020 13,916,164      
Beginning Balance at Sep. 30, 2020 $ 1,391 101,896,586 (87,302,302) 14,595,675
Net loss (3,057,807)  
Ending Balance, Shares at Dec. 31, 2020 13,957,792      
Ending Balance at Dec. 31, 2020 $ 1,391 103,433,515 (90,360,109) 13,074,797
Stock based compensation 1,536,929  
Net loss (2,992,868) $ (2,992,868)
Ending Balance, Shares at Mar. 31, 2021       928,221
Ending Balance at Mar. 31, 2021 1,395 104,753,666 (93,352,977) $ 11,402,084
Stock based compensation 803,604 803,604
Cashless exercise of warrants
Cashless exercise of options, Shares 304      
Proceeds from exercise of warrants $ 4 $ 516,547 $ 516,551
Proceeds from exercise of warrants, Shares 41,324      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Background Information
 9 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background Information

 

1. Background Information

 

BioVie Inc. (the “Company”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

 

BioVie completed a Phase 2a clinical trial of BIV201 in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute in Richmond, VA in 2019. The Company met with representatives of the Food and Drug Administration (“FDA”) in a Type C Guidance Meeting to discuss the study results and plan our next clinical study. Subsequently we requested a Type B Meeting and submitted an extensive pre-meeting information package. In April 2020, the FDA provided a written response that provided new guidance regarding primary and secondary endpoints, BIV201 dosing levels, quality of life measures and other key aspects of the clinical trial design. After further communications, the Company completed the clinical trial design protocol and was cleared to begin a Phase 2 clinical study. We activated the first trial sites in the first calendar quarter of 2021 and patient screening is now underway. The Phase 2 study results will be used to guide the design of a pivotal Phase 3 clinical trial. We have developed a patent-pending novel liquid formulation of BIV201 for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version of terlipressin.

 

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company is applying for global patent coverage of a proprietary liquid formulation of terlipressin for use in the Phase 2 and Phase 3 clinical trials, which has been cleared by the FDA. This could eventually provide up to 20 years of patent protection in countries where the Company seeks patent issuance according to local patent laws.

 

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the  rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

 

On April 27, 2021, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with NeurMedix, Inc. (“NeurMedix”) and Acuitas Group Holdings, LLC (“Acuitas”), which are related party affiliates, pursuant to which the Company has agreed to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration of cash and shares of common stock. (collectively, the “Transaction”). The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease. See Note 9 - Subsequent Events.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Liquidity
 9 Months Ended
Mar. 31, 2021
Liquidity  
Liquidity

 

2. Liquidity

 

Liquidity and Going Concern

 

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2021, the Company had working capital of approximately $10 million and cash of $11.4 million and, stockholders’ equity was approximately $11.4 million, and its accumulated deficit was approximately $93.4 million. In addition, the Company has not generated any revenues and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. The emergence of widespread health emergencies or pandemics of the coronavirus ("Covid-19"), may lead to continued regional quarantines, business shutdowns, labor shortages, disruptions to supply chains, and overall economic instability, including the duration and spread of the outbreak and restrictions and the impact of Covid-19 on the financial markets and the overall economy, all of which are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s ability to raise funds may be materially adversely affected.

Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies
 9 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

3. Significant Accounting Policies

 

Basis of Presentation – Interim Financial Information

These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2020 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2020 and 2019 in our Annual Report on form 10-K filed with Securities Exchange Commission (“SEC”) on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10K for the fiscal year ended June 30, 2020 filed with the SEC on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020.

 BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited) 

 

3. Significant Accounting Policies (continued)

 

Loan Pursuant to Paycheck Protection Program

 

The Company received $62,500 in loan proceeds pursuant to the Paycheck Protection Program (“PPP”), under the Coronavirus Aid Relief and Economic Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement by and between the Company and Lender. The Company applied for the loan in May 2020 and received funding for its maximum amount of $62,500 on May 21, 2020. The term of the loan is for 60 months and matures on the fifth-year anniversary from the date of funding. It bears interest at an annual rate of 1%. The PPP loan is subject to 100% forgiveness. The Company has filed the application for forgiveness, in February 2021 and is pending confirmation of forgiveness by the SBA. There can be no assurance that such forgiveness will occur. The Company is accounting for the loan as debt and if forgiveness is granted the Company will recognize a gain on extinguishment.

   

Net (loss) income per Common Share

 

Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the nine months ended March 31, 2021 and 2020, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liability creating a net loss available to common shareholders. For the three months ended March 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to net loss for the period.

The table below shows the number of outstanding stock options and warrants as of March 31, 2021 and 2020:

   March 31, 2021  March 31, 2020
   Number of Shares  Number of Shares
Stock Options   755,200    68,400 
Warrants   173,021    1,374,667 
Total   928,221    1,443,067 

 

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. This ASU was adopted as of July 1, 2020. There has been no impact to its condensed financial statements and related disclosures.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets
 9 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

  

4. Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of March 31, 2021 and June 30, 2020:

   March 31, 2021  June 30, 2020
Intellectual Property  $2,293,770   $2,293,770 
Less Accumulated Amortization   (1,140,576)   (968,544)
Intellectual Property, Net  $1,153,194   $1,325,226 

 

Amortization expense for the three-month period ended March 31, 2021 and 2020 was $57,344 and $57,344 respectively. Amortization expense for the nine-month period ended March 31, 2021 and 2020 was $172,032 and $172,032 respectively.

 

Estimated future amortization expense is as follows:

 

   
Year ending June 30, 2021 (Remaining three months)  $                           57,344
2022                             229,377
2023                             229,377
2024                             229,377
2025                             229,377
2026                             178,342
Intellectual Property, Net  $                      1,153,194

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions
 9 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

 

5. Related Party Transactions

 

Equity Transactions with Acuitas

 

On September 22, 2020, concurrent with the closing of the Company’s Offering, approximately $1.8 million was paid to Acuitas satisfying all amounts owed on the Debenture due September 24, 2020 held by the Company’s controlling stockholder, Acuitas.

 

Additionally in connection with the close of the public offering on September 22, 2020, the Company issued an aggregate of 6,909,582 shares of Common Stock to Acuitas, representing (i) 5.4 million shares issuable pursuant to Acuitas’ rights under the Purchase Agreement dated July 3, 2018, as amended on June 24, 2019 and October 9, 2019; and the various extension letters as more fully described below; which resulted in a deemed dividend at the close of the public offering at price of $10 per share, consistent with the Company’s accounting policy; and (ii) the automatic exercise of 1.5 million warrants issued to Acuitas in connection with the Debenture financing at the par value of the Common Stock.

 

During the three months ended September 30, 2020, the Company received additional draws under the Debenture totaling $436,000. The total draws as of September 22, 2020 were $1.7 million and the related total number of warrants issuable at $4.00 per share of common stock was 424,750 of which 328,250 warrants had been issued. In accordance with the Debenture agreements, as more fully described below; at September 22, 2020 upon the Company’s close of its public offering, al1 the warrants issued related to the debenture totaling 1,453,250 were mandatorily redeemed along with the additional 96,500 shares common stock issued to Acuitas.

 

The following paragraphs summarize the background of those financings and arrangements which were settled and redeemed on September 22, 2020.

 

On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.

 

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us. 

 

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

5. Related Party Transactions (continued)

 

Each share of Preferred Stock automatically converted into 1 share of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.

 

Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:

 

-  

Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock; 

 

-  

Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq; 

 

-   Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.

 

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)  

 

5. Related Party Transactions (continued)

 

Convertible Debenture Transaction with Acuitas

 

On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s current reverse stock split or December 1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants.

 

Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.

 

The issuance of 1,125,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the year ended June 30, 2020, accordingly. A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of the unearned discount for the three-month period ended March 31, 2021 and 2020 of $0 and $20,307, respectively, and for the nine months period ended March 31, 2021 and 2020 of $21,336 and $41,902, respectively.

 

The Company received draws under the Debenture that totaled approximately $1.3 million during the year ended June 30, 2020. The total interest expense related to the draws under the Debenture was approximately $99,000 for the year ended June 30, 2020. On April 1, 2020, the Company entered an amendment to modify the payment of accrued interest amounts under the original terms of the Debenture to capitalize all such amounts as would otherwise accrue on the Debenture. On January 4, 2020, payment of $13,487 accrued interest due was paid through the issuance of 4,422 shares of the Company’s common stock. Acuitas and the Company continue to discuss the need and timing for some or all the remaining draws under the Debenture Agreement. Subsequent to the initial $500,000 draw on September 24, 2019, the Company received draws that totaled $813,000 as July 13, 2020, and accordingly; the Company issued additional Bridge Warrants to purchase 203,250 shares of common stock to its controlling stockholder under the terms of the Bridge Financing. Accordingly, on April 16, 2020, the Company recorded the warrants to purchase 125,000 common stock related to the second $500,000 draw under the debenture as a derivative warrant liability as of June 30, 2020. The Company recorded the warrants related to the draws totaling $313,000 to purchase 78,250 common shares as derivative liabilities.

 

 BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)  

 

5. Related Party Transactions (continued)

 

Pursuant to the 2019 Purchase Agreement, Acuitas agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.

 

Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:

 

  - The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;

 

  - Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and

 

  - The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto.

 

On July 14, 2020, the Company, entered into a further extension of its letter agreements dated April 8, 2020, that furthered extended its letter agreement dated February 10, 2020 with Acuitas regarding Acuitas’ previous agreement to modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life of the Company’s intellectual property rights and commitment to purchase such securities upon the closing of the Offering and commitment to purchase such additional securities would remain effective until October 31, 2020, and accordingly Acuitas was entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company’s current bridge financing with Acuitas were to be made based with respect to the Company’s ongoing capital requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith. The letter agreement of July 14, 2020 also confirmed the understanding between the Company and Acuitas regarding certain amounts funded to BioVie that were intended as “partial draws” of credit available under the Debenture which, as of July 14, 2020 hereof aggregated $813,000 in aggregate principal amount in additional to amounts initial funded under the Debenture. Accordingly, such “partial draws” accrued additional principal as amounts otherwise funded pursuant to the original schedule of draws included in the Debenture (as modified by the letter agreement between BioVie and Acuitas dated April 1, 2020 regarding the capitalization of interest otherwise payable) and shall entitle Acuitas to receive a pro rata amount of Bridge Warrants.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
 9 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

  

6. Fair Value Measurements

 

On September 22, 2020, concurrent with the closing of the Offering; the warrants related to derivative liabilities were automatically exercised in full and the convertible Debenture was paid off in cash expiring the conversion option. The fair value of the derivative liabilities - warrants and derivative liability - conversion option on convertible Debenture prior to redemption at September 22, 2020 was $13.1 million, and the change in the fair value of $8.3 million from June 30, 2020 was recorded in the accompanying condensed Statements of Operations. At September 22, 2020, the derivative liabilities, both the warrants and expired conversion option totaling $ 13.1 million were then recorded as additional paid in capital upon automatic exercise of the warrants and payoff of the Debenture.

 

At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

 

    Fair Value Measurements at
March 31, 2021
    Level 1    Level 2    Level 3    Total
                    
Derivative liability - Warrants  $—     $—     $—     $—  
Derivative liability -Conversion option on convertible debenture   —      —      —      —  
   Total derivatives  $—     $—     $—     $—  

 

   Fair Value Measurements at
   June 30, 2020
   Level 1  Level 2  Level 3  Total
             
Derivative liability - Warrants  $—     $—     $16,411,504   $16,411,504 
Derivative liability -Conversion option on convertible debenture   —      —      5,000,800    5,000,800 
   Total derivatives  $—     $—     $21,412,304   $21,412,304 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the nine months ended March 31, 2021:

  

   Derivative liabilities - Warrants  Derivative liability - Conversion Option on Convertible Debenture
       
Beginning balance at July 1, 2020  $16,411,504   $5,000,800 
Additions to level 3 liabilities   —      —   
Change in in fair value of level 3 liability   (6,054,121)   (2,225,798)
Transfer in and/or out of Level 3   (10,357,383)   (2,775,002)
Balance at March 31, 2021  $—     $—   

 


BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

6. Fair Value Measurements (continued)

 

Derivative liability – Warrants

 

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise. 

 

The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model. The valuation at June 30, 2020 used the following assumptions: stock price of $14, exercise price of $4.00, term of 5 year expiring April 2025, volatility of 76.61%, dividend yield of 0%, and risk-free interest rate of 0.29%.

 

The valuation at September 22, 2020 of the warrants associated with equity financing prior to their automatic exercise in full used were the following assumptions: stock price of $9.55, exercise price of $4.00, term of 4 year expiring September 2024, volatility of 79.69%, dividend yield of 0%, and risk-free interest rate of 0.21%. (See note 5 “Related Party Transactions”)

 

Derivative liability – Conversion option in convertible debenture

The Company recognized a derivative liability for the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture; which may be convertible into shares of common stock at $4.00 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The valuation at June 30, 2020 used the following assumptions: stock price of $14, conversion price of $4.00, term of 0.25 year expiring September 2020, volatility of 62.47%, dividend yield of 0%, and risk-free interest rate of 0.16%.

 

The valuation at September 22, 2020 used the following assumptions: stock price of $9.55, conversion price of $4.00, term of 0.008 year expiring September 2020, volatility of 45.49%, dividend yield of 0%, and risk-free interest rate of 0.01%.

 

The related Debenture was paid off in cash on September 22, 2020, expiring the conversion option. (See note 5 “Related Party Transactions”)
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions
 9 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Equity Transactions

 

7. Equity Transactions

 

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2021:

 

   Options  Weighted-Average Exercise Price  Weighted Remaining Average Contractual Term  Aggregate Intrinsic Value
Outstanding at June 30, 2020   60,400   $11.06    4.2   $352,600 
Granted   698,000    14.63    4.7    954,239 
Options Exercised or Forfeited   (3,200)   4.76    —      —   
Outstanding at March 31, 2021   755,200   $13.85    4.4   $1,516,511 
Exercisable at March 31, 2021   236,500   $13.85    4.4   $1,516,511 

 

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions for the nine months ended March 31, 2021 and 2020:

 

  March 31, 2021   March 31, 2020
Expected life of options (In years) 5   5
Expected volatility 77.05%   73.74%
Risk free interest rate 0.5%   1.63%
Dividend Yield 0%   0%

 

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $803,604 and $2,340,533 for the three- and nine- month periods ended March 31, 2021, respectively, and $13,684 and $24,846 for the three- and nine- month periods ended March 31, 2020, respectively.

As of March 31, 2021, unrecognized stock-based compensation cost was $3,721,620 which is expected to be recognized over a weighted-average period of approximately 3 years.

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

7. Equity Transactions (continued)

 

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2021:

 

Exercise Price  Outstanding  Weighted Average Contract Life  Exercisable
$2.80    7,200    3.8    7,200 
$3.75    4,800    2.8    4,800 
$6.25    1,600    2.6    1,600 
$7.50    25,600    4.9    25,600 
$8.75    1,600    3.0    1,600 
$9.54    800    4.5    800 
$9.90    800    4.5    800 
$12.50    4,000    1.8    4,000 
$13.91    691,600    4.7    172,900 
$25.00    1,600    1.5    1,600 
$26.25    4,400    1.1    4,400 
$27.50    800    1.0    800 
$28.75    1,600    1.4    1,600 
$31.25    4,000    0.6    4,000 
$42.09    4,800    4.8    4,800 

 

Stock Warrants

 

The following table summarizes the warrants activity during the nine months ended March 31, 2021:

 

   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Life (Years)  Aggregate Intrinsic Value
Outstanding and exercisable at June 30, 2020   1,374,667   $7.72    4.2   $13,799,331 
Granted   293,248   $6.61    5.0   $—   
Expired   —     $—      —     $—   
Exercised   (41,644)  $12.40    4.0   $—   
Exercised - Acuitas   (1,453,250)  $4.00    4.0   $—   
Outstanding and exercisable at March 31, 2020   173,021   $10.49    3.4   $2,203,264 

 

Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,815 expire in fiscal year ending June 30, 2023, 110,140 expire in fiscal year ending June 30, 2025 and 48,675 expire in fiscal year ending June 30, 2026. 

 

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

7. Equity Transactions (continued)

 

Issuance of common stock through exercise of Stock Options and Warrants

On July 28, 2020, the Company issued 2,210 shares of common stock pursuant to a cashless exercise of stock options to purchase 3,200 shares at an average exercise price of $4.76 per share.

 

On January 27, 2021, the Company issued 304 shares of common stock pursuant to a cashless exercise of warrants to purchase 320 shares at an average exercise price of $1.88 per share.

 

On March 23, 2021, the Company issued 27,000 shares of common stock pursuant to a cash exercise of warrants to purchase 27,000 shares at an average exercise price of $12.50 per share.

 

On March 24, 2021, the Company issued 14,324 shares of common stock pursuant to a cash exercise of warrants to purchase 14,324 shares at an average exercise price of $12.50 per share.

 

Issuance of warrants

On July 13, 2020, the Company issued Warrants to purchase 203,250 shares of common stock to its controlling stockholder under the terms of the Bridge Financing. The warrants were exercisable at an exercise price of $4 at any time from the date of issuance until 5 years from the date of issuance. (See Note 5 Related Party Transactions.)

On September 22, 2020, the Company issued warrants to purchase 89,998 shares of common stock to the underwriters of the Offering in connection with the close of the Offering of registered Common Stock The warrants are exercisable at an exercise price of $12.50 at any time from date of issuance until 5 years from the date of issuance.

Issuance of stock options

On October 1, 2020, the Company issued stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $9.54 at any time from date of issuance and expire 5 years from the date of issuance.

 

On October 13, 2020, the Company issued stock options to purchase 800 shares of common stock as part of the annual board of director compensation. The stock options were issued and are exercisable at $9.90 at any time from date of issuance and expire 5 years from the date of issuance.

 

On December 18, 2020, the Company issued stock options to purchase 691,600 shares of common stock as part of the annual board of director compensation. The stock options have a vesting period, where 25% of the stock options vest on the grant date, and the remaining 75% vest over a 3 year period, on the first, second, and third anniversary of the grant date. The stock options were issued and are exercisable at $13.91 at any time from date of issuance and expire 5 years from the date of issuance. The amortization for the quarter ended March 31, 2021 was $679,276. The remaining amortization over the next 5 years is $3,721,610.

 

On January 19, 2021, the Company issued stock option grants to purchase a total of 4,800 shares of common stock, granting 800 shares each to the Chief Operations Officer, the Chief Scientific Officer and to four of its key consultants as part of their annual compensation. The stock options were issued and are exercisable at $42.09 at any time from date of issuance and expire 5 years from the date of issuance.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
 9 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

 

8. Commitments and Contingencies 

 

Office Lease 

On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.

Challenge to US Patent

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

 

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

 

This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2 and Phase 3 trials, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country. 

 

Royalty Agreements

 

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

 

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2021 and 2020

(unaudited)

 

8. Commitments and Contingencies (continued) 

 

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally, the Company obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy).

 

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
 9 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

 

9. Subsequent Events 

 

On April 19, 2021, the Company issued 724 shares of common stock pursuant to a cashless exercise of warrants to purchase 760 shares at an average exercise price of $1.88 per share.

 

On April 30, 2021, the Company issued 13,500 shares of common stock pursuant a cash exercise of warrants at $12.50 per share.

 

On April 27, 2021, the Company entered into a Purchase Agreement with NeurMedix, and Acuitas, which are related party affiliates, pursuant to which the Company has agreed to acquire certain assets from NeurMedix and assume certain liabilities of NeurMedix, in exchange for the consideration described below. The acquired assets include, among others, those related to certain drug candidates being developed by NeurMedix, including NE3107, a small molecule orally administered inhibitor of insulin resistance and the pathological inflammatory cascade, with a novel mechanism of action that has potential applications for treatment against Alzheimer’s Disease and Parkinson’s Disease.

 

At the closing of the Transaction, BioVie will issue to NeurMedix 8,361,308 shares of the Company’s common stock and make a cash payment equal to the aggregate amount of NeurMedix’s direct and documented cash expenditures to advance certain clinical programs from March 1, 2021 through the closing, which cash payment is estimated to be approximately $3.0 million. Subject to the terms and conditions of the Purchase Agreement, following the closing, BioVie will also be obligated to deliver contingent consideration to NeurMedix (or its successor) consisting of (i) a cash payment of approximately $7.3 million, subject to a pivotal clinical trial for NE3107 meeting its primary endpoint(s) and BioVie having successfully raised at least $50 million in new capital, and (ii) shares of BioVie’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by the Company from NeurMedix, as more fully set forth in the Purchase Agreement.

 

On May 9, 2021, the Company, NeurMedix and Acuitas entered into Amendment No. 1 to the APA (the “Amendment” and the APA as so amended, the “Purchase Agreement”), pursuant to which the parties agreed, among other things, to modify the contingent stock consideration that BioVie may be obligated to deliver to NeurMedix (or its successor) pursuant to the Purchase Agreement. Previously, BioVie was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of BioVie’s common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by BioVie from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 89.9999% of BioVie’s issued and outstanding common stock. Pursuant to the Amendment, BioVie will be obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of up to 18.0 million shares of BioVie’s common stock, with 4.5 million shares issuable upon the achievement of each of the four milestones set forth in the Purchase Agreement, subject to a cap limiting the issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affiliates exceeding 87.5% of BioVie’s issued and outstanding common stock.

 

The Transaction is expected to close twenty calendar days after a related definitive information statement on Schedule 14C is mailed to the Company’s stockholders and is anticipated to close in the second calendar quarter of 2021.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation – Interim Financial Information

Basis of Presentation – Interim Financial Information

These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2020 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2020 and 2019 in our Annual Report on form 10-K filed with Securities Exchange Commission (“SEC”) on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10K for the fiscal year ended June 30, 2020 filed with the SEC on August 6, 2020, and as amended by Amendment No. 1 on Form 10-K/A and filed with the SEC on August 7, 2020.
Loan Pursuant to Paycheck Protection Program

Loan Pursuant to Paycheck Protection Program

 

The Company received $62,500 in loan proceeds pursuant to the Paycheck Protection Program (“PPP”), under the Coronavirus Aid Relief and Economic Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement by and between the Company and Lender. The Company applied for the loan in May 2020 and received funding for its maximum amount of $62,500 on May 21, 2020. The term of the loan is for 60 months and matures on the fifth-year anniversary from the date of funding. It bears interest at an annual rate of 1%. The PPP loan is subject to 100% forgiveness. The Company has filed the application for forgiveness, in February 2021 and is pending confirmation of forgiveness by the SBA. There can be no assurance that such forgiveness will occur. The Company is accounting for the loan as debt and if forgiveness is granted the Company will recognize a gain on extinguishment.
Net (loss) income per Common Share

Net (loss) income per Common Share

 

Basic net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the nine months ended March 31, 2021 and 2020, all potential securities were anti-dilutive as a result of the effect of the change in fair value of the derivative liability creating a net loss available to common shareholders. For the three months ended March 31, 2021 and 2020, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to net loss for the period.

The table below shows the number of outstanding stock options and warrants as of March 31, 2021 and 2020:

   March 31, 2021  March 31, 2020
   Number of Shares  Number of Shares
Stock Options   755,200    68,400 
Warrants   173,021    1,374,667 
Total   928,221    1,443,067 
Recent accounting pronouncements

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. This ASU was adopted as of July 1, 2020. There has been no impact to its condensed financial statements and related disclosures.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Tables)
 9 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
number of outstanding stock options and warrants

The table below shows the number of outstanding stock options and warrants as of March 31, 2021 and 2020:
Significant Accounting Policies
   March 31, 2021  March 31, 2020
   Number of Shares  Number of Shares
Stock Options   755,200    68,400 
Warrants   173,021    1,374,667 
Total   928,221    1,443,067 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Tables)
 9 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of the intangible assets
Intangible Assets
   March 31, 2021  June 30, 2020
Intellectual Property  $2,293,770   $2,293,770 
Less Accumulated Amortization   (1,140,576)   (968,544)
Intellectual Property, Net  $1,153,194   $1,325,226 
Estimated future amortization expense

Estimated future amortization expense is as follows:

 
Intangible Assets (Details 2)
   
Year ending June 30, 2021 (Remaining three months)  $                           57,344
2022                             229,377
2023                             229,377
2024                             229,377
2025                             229,377
2026                             178,342
Intellectual Property, Net  $                      1,153,194
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
 9 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

 
Fair Value Measurements
    Fair Value Measurements at
March 31, 2021
    Level 1    Level 2    Level 3    Total
                    
Derivative liability - Warrants  $—     $—     $—     $—  
Derivative liability -Conversion option on convertible debenture   —      —      —      —  
   Total derivatives  $—     $—     $—     $—  
activity for liabilities measured at fair value using unobservable inputs

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the nine months ended March 31, 2021:

  
Fair Value Measurements (Details 2)
   Derivative liabilities - Warrants  Derivative liability - Conversion Option on Convertible Debenture
       
Beginning balance at July 1, 2020  $16,411,504   $5,000,800 
Additions to level 3 liabilities   —      —   
Change in in fair value of level 3 liability   (6,054,121)   (2,225,798)
Transfer in and/or out of Level 3   (10,357,383)   (2,775,002)
Balance at March 31, 2021  $—     $—   
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions (Tables)
 9 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
activity relating to the Company’s stock options

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2021:

 
Equity Transactions
   Options  Weighted-Average Exercise Price  Weighted Remaining Average Contractual Term  Aggregate Intrinsic Value
Outstanding at June 30, 2020   60,400   $11.06    4.2   $352,600 
Granted   698,000    14.63    4.7    954,239 
Options Exercised or Forfeited   (3,200)   4.76    —      —   
Outstanding at March 31, 2021   755,200   $13.85    4.4   $1,516,511 
Exercisable at March 31, 2021   236,500   $13.85    4.4   $1,516,511 
weighted-average assumptions

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions for the nine months ended March 31, 2021 and 2020:

 
Equity Transactions (Details 2)
  March 31, 2021   March 31, 2020
Expected life of options (In years) 5   5
Expected volatility 77.05%   73.74%
Risk free interest rate 0.5%   1.63%
Dividend Yield 0%   0%
summary of stock options outstanding and exercisable by exercise price

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2021:

 
Equity Transactions (Details 3)
Exercise Price  Outstanding  Weighted Average Contract Life  Exercisable
$2.80    7,200    3.8    7,200 
$3.75    4,800    2.8    4,800 
$6.25    1,600    2.6    1,600 
$7.50    25,600    4.9    25,600 
$8.75    1,600    3.0    1,600 
$9.54    800    4.5    800 
$9.90    800    4.5    800 
$12.50    4,000    1.8    4,000 
$13.91    691,600    4.7    172,900 
$25.00    1,600    1.5    1,600 
$26.25    4,400    1.1    4,400 
$27.50    800    1.0    800 
$28.75    1,600    1.4    1,600 
$31.25    4,000    0.6    4,000 
$42.09    4,800    4.8    4,800 
summarizes the warrants activity

The following table summarizes the warrants activity during the nine months ended March 31, 2021:

 
Equity Transactions (Details 4)
   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Life (Years)  Aggregate Intrinsic Value
Outstanding and exercisable at June 30, 2020   1,374,667   $7.72    4.2   $13,799,331 
Granted   293,248   $6.61    5.0   $—   
Expired   —     $—      —     $—   
Exercised   (41,644)  $12.40    4.0   $—   
Exercised - Acuitas   (1,453,250)  $4.00    4.0   $—   
Outstanding and exercisable at March 31, 2020   173,021   $10.49    3.4   $2,203,264 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Details) - shares
Mar. 31, 2021
Mar. 31, 2020
Summary of Investment Holdings [Line Items]    
Shares, Outstanding 928,221 1,443,067
Warrant [Member]    
Summary of Investment Holdings [Line Items]    
Shares, Outstanding 173,021 1,374,667
Equity Option [Member]    
Summary of Investment Holdings [Line Items]    
Shares, Outstanding 755,200 68,400
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Intellectual Property $ 2,293,770 $ 2,293,770
Less Accumulated Amortization (1,140,576) (968,544)
Intellectual Property, Net $ 1,153,194 $ 1,325,226
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Details 2) - USD ($)
$ in Thousands
Mar. 31, 2021
Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Year ending June 30, 2021 (Remaining three months) $ 57,344  
2022 229,377  
2023 229,377  
2024 229,377  
2025 229,377  
2026 178,342  
Intellectual Property, Net $ 1,153,194 $ 1,325,226
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions (Details Narrative) - shares
Mar. 31, 2021
Sep. 22, 2020
Jun. 30, 2020
Related Party Transaction [Line Items]      
Common Stock, Shares, Issued 13,957,792   5,204,392
Acuitas Group Holdings L L C [Member]      
Related Party Transaction [Line Items]      
Common Stock, Shares, Issued   6,909,582  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Details) - USD ($)
Mar. 31, 2021
Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability $ 21,412,304
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability 21,412,304
Derivative Liability Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability 16,411,504
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability 16,411,504
Derivative Liability Conversion Option On Convertible Debenture [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability 5,000,800
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability $ 5,000,800
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Details 2)
 9 Months Ended
Mar. 31, 2021
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance at July 1, 2020 $ 21,412,304
Balance at March 31, 2021
Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance at July 1, 2020 21,412,304
Balance at March 31, 2021
Derivative Liability Warrants [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance at July 1, 2020 16,411,504
Balance at March 31, 2021
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance at July 1, 2020 16,411,504
Additions to level 3 liabilities
Change in in fair value of level 3 liability (6,054,121)
Transfer in and/or out of Level 3 (10,357,383)
Balance at March 31, 2021
Derivative Liability Conversion Option On Convertible Debenture [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance at July 1, 2020 5,000,800
Balance at March 31, 2021
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Beginning balance at July 1, 2020 5,000,800
Additions to level 3 liabilities
Change in in fair value of level 3 liability (2,225,798)
Transfer in and/or out of Level 3 (2,775,002)
Balance at March 31, 2021
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Details Narrative) - Fair Value, Inputs, Level 3 [Member] - $ / shares
 3 Months Ended 9 Months Ended
Sep. 22, 2020
Jun. 30, 2020
Derivative Liability Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Share Price $ 9.55 $ 14
Exercise Price $ 4.00 $ 4.00
Term 4 years 5 years
Volatility Rate 79.69% 76.61%
Dividend Yield 0.00% 0.00%
Risk-Free Interest Rate 0.21% 0.29%
Derivative Liability Conversion Option On Convertible Debenture [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Share Price $ 9.55 $ 14
Exercise Price $ 4.00 $ 4.00
Term   3 months
Volatility Rate 45.49% 62.47%
Dividend Yield 0.00% 0.00%
Risk-Free Interest Rate 0.01% 0.16%
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions (Details) - USD ($)
 9 Months Ended
Mar. 24, 2021
Mar. 23, 2021
Jan. 27, 2021
Jan. 19, 2021
Dec. 18, 2020
Oct. 13, 2020
Oct. 02, 2020
Jul. 28, 2020
Mar. 31, 2021
Summary of Investment Holdings [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (14,324) (27,000) (320)         (3,200)  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 12.50 $ 12.50 $ 1.88         $ 4.76  
Equity Option [Member]                  
Summary of Investment Holdings [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance                 60,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance                 $ 11.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term                 4 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding at beginning of period                 $ 352,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       4,800 691,600 800 800   698,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price       $ 42.09 $ 13.91 $ 9.90 $ 9.54   $ 14.63
Weighted Remaining Average Contractual Term, Granted       5 years 5 years 5 years 5 years   4 years 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested                 $ 954,239
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period                 (3,200)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price                 $ 4.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance                 755,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance                 $ 13.85
Weighted Remaining Average Contractual Term, Ending Balance                 4 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding at end of period                 $ 1,516,511
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number                 236,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price                 $ 13.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term                 4 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value                 $ 1,516,511
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions (Details 2) - Equity Option [Member]
 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Summary of Investment Holdings [Line Items]    
Expected life of options (In years) 5 years 5 years
Expected volatility 77.05% 73.74%
Risk free interest rate 0.50% 1.63%
Dividend Yield 0.00% 0.00%
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions (Details 3)
 9 Months Ended
Mar. 31, 2021
$ / shares
shares
Stock Option 1 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 2.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 7,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 7,200
Weighted Average Contractual Life 3 years 9 months 18 days
Stock Option 2 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4,800
Weighted Average Contractual Life 2 years 9 months 18 days
Stock Option 3 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 6.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 1,600
Weighted Average Contractual Life 2 years 7 months 6 days
Stock Option 4 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 7.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 25,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 25,600
Weighted Average Contractual Life 4 years 10 months 24 days
Stock Option 5 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 1,600
Weighted Average Contractual Life 3 years
Stock Option 6 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 9.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 800
Weighted Average Contractual Life 4 years 6 months
Stock Option 7 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 9.90
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 800
Weighted Average Contractual Life 4 years 6 months
Stock Option 8 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 12.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4,000
Weighted Average Contractual Life 1 year 9 months 18 days
Stock Option 9 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 13.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 691,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 172,900
Weighted Average Contractual Life 4 years 8 months 12 days
Stock Option 10 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 25.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 1,600
Weighted Average Contractual Life 1 year 6 months
Stock Option 11 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 26.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4,400
Weighted Average Contractual Life 1 year 1 month 6 days
Stock Option 12 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 27.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 800
Weighted Average Contractual Life 1 year
Stock Option 13 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 28.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 1,600
Weighted Average Contractual Life 1 year 4 months 24 days
Stock Option 14 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 31.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4,000
Weighted Average Contractual Life 7 months 6 days
Stock Option 15 [Member]  
Summary of Investment Holdings [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 42.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4,800
Weighted Average Contractual Life 4 years 9 months 18 days
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions (Details 4) - Warrant [Member] - USD ($)
 9 Months Ended
Sep. 22, 2020
Jul. 13, 2020
Mar. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Warrant Outstanding, at the beginning of the period     1,374,667
Weighted Average Exercise Price, at the beginning of the period     $ 7.72
Weighted Average Remaining Life, at the beginning of the period     4 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding at beginning of period     $ 13,799,331
Warrant Outstanding, at the beginning of the period 89,998 203,250 293,248
Weighted Average Exercise Price, at the beginning of the period $ 12.50 $ 4 $ 6.61
Weighted Average Remaining Life, Granted 5 years 5 years 5 years
Warrant Outstanding, at the beginning of the period    
Weighted Average Exercise Price, at the beginning of the period    
Warrant Exercised     (41,644)
Weighted Average Exercise Price, Exercised     $ 12.40
Weighted Average Remaining Life, Exercised     4 years
Warrant Exercised - Acuitas     (1,453,250)
Weighted Average Exercise Price, Exercised - Acuitas     $ 4.00
Weighted Average Remaining Life, Exercised - Acuitas     4 years
Warrant Outstanding, at the end of period     173,021
Weighted Average Exercise Price, at the end of period     $ 10.49
Weighted Average Remaining Life, at the end of period     3 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding at end of period     $ 2,203,264
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Transactions (Details Narrative) - USD ($)
 3 Months Ended 4 Months Ended 9 Months Ended
Mar. 24, 2021
Mar. 23, 2021
Jan. 27, 2021
Jan. 19, 2021
Dec. 18, 2020
Oct. 13, 2020
Oct. 02, 2020
Sep. 22, 2020
Jul. 28, 2020
Jul. 13, 2020
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Summary of Investment Holdings [Line Items]                                    
Share-based Payment Arrangement, Noncash Expense                     $ 803,604     $ 13,684 $ 11,162 $ 1,536,929 $ 2,340,533 $ 24,846
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 14,324 27,000 320           3,200                  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 12.50 $ 12.50 $ 1.88           $ 4.76                  
Common Stock [Member]                                    
Summary of Investment Holdings [Line Items]                                    
Share-based Payment Arrangement, Noncash Expense                              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 14,324 27,000 304           2,210   304   2,210          
Warrant [Member]                                    
Summary of Investment Holdings [Line Items]                                    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period               89,998   203,250             293,248  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share               $ 12.50   $ 4             $ 6.61  
Exercisable period of Warrant               5 years   5 years             5 years  
Equity Option [Member]                                    
Summary of Investment Holdings [Line Items]                                    
Non-vested Options Granted       4,800 691,600 800 800                   698,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period                                 3,200  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price                                 $ 4.76  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price       $ 42.09 $ 13.91 $ 9.90 $ 9.54                   $ 14.63  
[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1]       5 years 5 years 5 years 5 years                   4 years 8 months 12 days  
Equity Option [Member] | Director [Member]                                    
Summary of Investment Holdings [Line Items]                                    
Non-vested Options Granted                                 3,721,620  
Weighted Average Period for Recognition                                 3 years  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details Narrative) - $ / shares
 3 Months Ended
Apr. 30, 2021
Apr. 19, 2021
Mar. 24, 2021
Mar. 23, 2021
Jan. 27, 2021
Jul. 28, 2020
Mar. 31, 2021
Sep. 30, 2020
Subsequent Event [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period     14,324 27,000 320 3,200    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price     $ 12.50 $ 12.50 $ 1.88 $ 4.76    
Common Stock [Member]                
Subsequent Event [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period     14,324 27,000 304 2,210 304 2,210
Subsequent Event [Member]                
Subsequent Event [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   760            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 12.50 $ 1.88            
Subsequent Event [Member] | Common Stock [Member]                
Subsequent Event [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 13,500 724            
EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 147 255 1 false 28 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanoantibiotics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://nanoantibiotics.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://nanoantibiotics.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Changes in Stockholders' (Deficit) Equity Sheet http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity Condensed Statements of Changes in Stockholders' (Deficit) Equity Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://nanoantibiotics.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity Sheet http://nanoantibiotics.com/role/Liquidity Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://nanoantibiotics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://nanoantibiotics.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://nanoantibiotics.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://nanoantibiotics.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Equity Transactions Sheet http://nanoantibiotics.com/role/EquityTransactions Equity Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://nanoantibiotics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://nanoantibiotics.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://nanoantibiotics.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://nanoantibiotics.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Intangible Assets (Tables) Sheet http://nanoantibiotics.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://nanoantibiotics.com/role/IntangibleAssets 18 false false R19.htm 00000019 - Disclosure - Fair Value Measurements (Tables) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://nanoantibiotics.com/role/FairValueMeasurements 19 false false R20.htm 00000020 - Disclosure - Equity Transactions (Tables) Sheet http://nanoantibiotics.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://nanoantibiotics.com/role/EquityTransactions 20 false false R21.htm 00000021 - Disclosure - Significant Accounting Policies (Details) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Details) Sheet http://nanoantibiotics.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://nanoantibiotics.com/role/IntangibleAssetsTables 22 false false R23.htm 00000023 - Disclosure - Intangible Assets (Details 2) Sheet http://nanoantibiotics.com/role/IntangibleAssetsDetails2 Intangible Assets (Details 2) Details http://nanoantibiotics.com/role/IntangibleAssetsTables 23 false false R24.htm 00000024 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://nanoantibiotics.com/role/RelatedPartyTransactions 24 false false R25.htm 00000025 - Disclosure - Fair Value Measurements (Details) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 25 false false R26.htm 00000026 - Disclosure - Fair Value Measurements (Details 2) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 26 false false R27.htm 00000027 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 27 false false R28.htm 00000028 - Disclosure - Equity Transactions (Details) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails Equity Transactions (Details) Details http://nanoantibiotics.com/role/EquityTransactionsTables 28 false false R29.htm 00000029 - Disclosure - Equity Transactions (Details 2) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails2 Equity Transactions (Details 2) Details http://nanoantibiotics.com/role/EquityTransactionsTables 29 false false R30.htm 00000030 - Disclosure - Equity Transactions (Details 3) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails3 Equity Transactions (Details 3) Details http://nanoantibiotics.com/role/EquityTransactionsTables 30 false false R31.htm 00000031 - Disclosure - Equity Transactions (Details 4) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails4 Equity Transactions (Details 4) Details http://nanoantibiotics.com/role/EquityTransactionsTables 31 false false R32.htm 00000032 - Disclosure - Equity Transactions (Details Narrative) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://nanoantibiotics.com/role/EquityTransactionsTables 32 false false R33.htm 00000033 - Disclosure - Subsequent Events (Details Narrative) Sheet http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://nanoantibiotics.com/role/SubsequentEvents 33 false false All Reports Book All Reports bivi-20210331_10q.htm bivi-20210331.xsd bivi-20210331_10qex31z1.htm bivi-20210331_10qex31z2.htm bivi-20210331_10qex32z1.htm bivi-20210331_10qex32z2.htm bivi-20210331_cal.xml bivi-20210331_def.xml bivi-20210331_lab.xml bivi-20210331_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bivi-20210331_10q.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 147, "dts": { "calculationLink": { "local": [ "bivi-20210331_cal.xml" ] }, "definitionLink": { "local": [ "bivi-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bivi-20210331_10q.htm" ] }, "labelLink": { "local": [ "bivi-20210331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bivi-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bivi-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 301, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 70, "http://nanoantibiotics.com/20210331": 12, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 87 }, "keyCustom": 37, "keyStandard": 218, "memberCustom": 18, "memberStandard": 10, "nsprefix": "bivi", "nsuri": "http://nanoantibiotics.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nanoantibiotics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Intangible Assets", "role": "http://nanoantibiotics.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Related Party Transactions", "role": "http://nanoantibiotics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Fair Value Measurements", "role": "http://nanoantibiotics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Equity Transactions", "role": "http://nanoantibiotics.com/role/EquityTransactions", "shortName": "Equity Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments and Contingencies", "role": "http://nanoantibiotics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Subsequent Events", "role": "http://nanoantibiotics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Intangible Assets (Tables)", "role": "http://nanoantibiotics.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Fair Value Measurements (Tables)", "role": "http://nanoantibiotics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)", "role": "http://nanoantibiotics.com/role/BalanceSheets", "shortName": "Condensed Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Equity Transactions (Tables)", "role": "http://nanoantibiotics.com/role/EquityTransactionsTables", "shortName": "Equity Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Significant Accounting Policies (Details)", "role": "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureSignificantAccountingPoliciesDetailsAbstract", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureIntangibleAssetsDetailsAbstract", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Intangible Assets (Details)", "role": "http://nanoantibiotics.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureIntangibleAssetsDetailsAbstract", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureIntangibleAssetsDetails2Abstract", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Intangible Assets (Details 2)", "role": "http://nanoantibiotics.com/role/IntangibleAssetsDetails2", "shortName": "Intangible Assets (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureIntangibleAssetsDetails2Abstract", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-09-22_custom_AcuitasGroupHoldingsLLCMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Fair Value Measurements (Details)", "role": "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Fair Value Measurements (Details 2)", "role": "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "shortName": "Fair Value Measurements (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureFairValueMeasurementsDetails2Abstract", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-012021-03-31_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-09-22_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Fair Value Measurements (Details Narrative)", "role": "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative", "shortName": "Fair Value Measurements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-09-22_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2021-03-222021-03-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Equity Transactions (Details)", "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails", "shortName": "Equity Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetailsAbstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-06-30_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetails2Abstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-012021-03-31_us-gaap_StockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Equity Transactions (Details 2)", "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "shortName": "Equity Transactions (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetails2Abstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-012021-03-31_us-gaap_StockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnearnedPremiums", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "role": "http://nanoantibiotics.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnearnedPremiums", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetails3Abstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31_custom_StockOption1Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Equity Transactions (Details 3)", "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails3", "shortName": "Equity Transactions (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetails3Abstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2021-03-31_custom_StockOption1Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetails4Abstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Equity Transactions (Details 4)", "role": "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "shortName": "Equity Transactions (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bivi:DisclosureEquityTransactionsDetails4Abstract", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2020-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2021-01-012021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Equity Transactions (Details Narrative)", "role": "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "shortName": "Equity Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-09-012020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2021-03-222021-03-24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2021-04-182021-04-19_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2021-01-012021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "role": "http://nanoantibiotics.com/role/StatementsOfOperations", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2021-01-012021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)", "role": "http://nanoantibiotics.com/role/StatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": "0", "lang": null, "name": "bivi:InterestExpenseFromConvertibleDebenture", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "AsOf2019-06-30_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Statements of Changes in Stockholders' (Deficit) Equity", "role": "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity", "shortName": "Condensed Statements of Changes in Stockholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2019-07-012019-09-30_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "bivi:IssuanceOfCommitmentShares", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Background Information", "role": "http://nanoantibiotics.com/role/BackgroundInformation", "shortName": "Background Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Liquidity", "role": "http://nanoantibiotics.com/role/Liquidity", "shortName": "Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "bivi:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Significant Accounting Policies", "role": "http://nanoantibiotics.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bivi-20210331_10q.htm", "contextRef": "From2020-07-01to2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "bivi_AcuitasGroupHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acuitas Group Holdings L L C [Member]" } } }, "localname": "AcuitasGroupHoldingsLLCMember", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_ConvertibleDebentureRelatedParty": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible debenture - related party, net of unearned discount of $0 and $462,864 and capitalized accrued interest of $0 and $48,407 at March 31, 2021 and June 30, 2020, respectively" } } }, "localname": "ConvertibleDebentureRelatedParty", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "bivi_DeemedDividend": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deemed dividends - Related Party", "verboseLabel": "Deemed dividends - related party" } } }, "localname": "DeemedDividend", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bivi_DeemedDividendForCommitmentShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deemed dividend for purchase option - related party" } } }, "localname": "DeemedDividendForCommitmentShares", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "bivi_DeemedDividendForPurchaseOptionRelatedPartyInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deemed dividend for purchase option - related party, Shares" } } }, "localname": "DeemedDividendForPurchaseOptionRelatedPartyInShares", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "bivi_DerivativeLiabilitiesConversionOptionCurrent": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative liability - conversion option on convertible debenture" } } }, "localname": "DerivativeLiabilitiesConversionOptionCurrent", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "bivi_DerivativeLiabilitiesWarrantCurrent": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative liability - warrants" } } }, "localname": "DerivativeLiabilitiesWarrantCurrent", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability Conversion Option On Convertible Debenture [Member]" } } }, "localname": "DerivativeLiabilityConversionOptionOnConvertibleDebentureMember", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_DerivativeLiabilityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability Warrants [Member]" } } }, "localname": "DerivativeLiabilityWarrantsMember", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bivi_DisclosureEquityTransactionsDetails2Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Transactions (Details 2)" } } }, "localname": "DisclosureEquityTransactionsDetails2Abstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureEquityTransactionsDetails3Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Transactions (Details 3)" } } }, "localname": "DisclosureEquityTransactionsDetails3Abstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureEquityTransactionsDetails4Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Transactions (Details 4)" } } }, "localname": "DisclosureEquityTransactionsDetails4Abstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureEquityTransactionsDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureEquityTransactionsDetailsAbstract", "verboseLabel": "Equity Transactions" } } }, "localname": "DisclosureEquityTransactionsDetailsAbstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureFairValueMeasurementsDetails2Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details 2)" } } }, "localname": "DisclosureFairValueMeasurementsDetails2Abstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureFairValueMeasurementsDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureFairValueMeasurementsDetailsAbstract", "verboseLabel": "Fair Value Measurements" } } }, "localname": "DisclosureFairValueMeasurementsDetailsAbstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureIntangibleAssetsDetails2Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details 2)" } } }, "localname": "DisclosureIntangibleAssetsDetails2Abstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureIntangibleAssetsDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureIntangibleAssetsDetailsAbstract", "verboseLabel": "Intangible Assets" } } }, "localname": "DisclosureIntangibleAssetsDetailsAbstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "bivi_DisclosureLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "localname": "DisclosureLiquidityAbstract", "nsuri": "http://nanoantibiotics.com/20210331", "xbrltype": "stringItemType" }, "bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureSignificantAccountingPoliciesDetailsAbstract", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "DisclosureSignificantAccountingPoliciesDetailsAbstract", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "bivi_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "weighted-average assumptions" } } }, "localname": "FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "bivi_InterestExpenseFromConvertibleDebenture": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Interest expense from convertible debenture" } } }, "localname": "InterestExpenseFromConvertibleDebenture", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_IssuanceOfCommitmentShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of commitment shares" } } }, "localname": "IssuanceOfCommitmentShares", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "bivi_IssuanceOfCommitmentSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of commitment shares, Shares" } } }, "localname": "IssuanceOfCommitmentSharesShares", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "bivi_LiquidityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LiquidityTextBlock", "verboseLabel": "Liquidity" } } }, "localname": "LiquidityTextBlock", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "bivi_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Pursuant to Paycheck Protection Program [Policy Text Block]", "label": "Loan Pursuant to Paycheck Protection Program" } } }, "localname": "LoanPursuantToPaycheckProtectionProgramPolicyTextBlock", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bivi_PaymentOfConvertibleDebentureRelatedParty": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentOfConvertibleDebentureRelatedParty", "negatedLabel": "Payment of convertible debenture - related party" } } }, "localname": "PaymentOfConvertibleDebentureRelatedParty", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_ProceedsFromConvertibleDebentureRelatedParty": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from convertible debenture - related party" } } }, "localname": "ProceedsFromConvertibleDebentureRelatedParty", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_ProceedsFromIssuanceOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants, Shares" } } }, "localname": "ProceedsFromIssuanceOfWarrantsShares", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of warrants\u00a0\u00a0- related party" } } }, "localname": "RedemptionOfWarrantsAndPurchaseOptionRelatedParty", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "bivi_RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption of warrants - related party, Shares" } } }, "localname": "RedemptionOfWarrantsAndPurchaseOptionRelatedPartyInShares", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised - Acuitas" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, Granted", "verboseLabel": "Exercisable period of Warrant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, at the end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms4": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms4", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms5": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Life, Exercised - Acuitas" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms5", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease1", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Remaining Average Contractual Term, Granted", "verboseLabel": "[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Remaining Average Contractual Term, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails" ], "xbrltype": "durationItemType" }, "bivi_StockOption10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 10 [Member]" } } }, "localname": "StockOption10Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption11Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 11 [Member]" } } }, "localname": "StockOption11Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption12Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 12 [Member]" } } }, "localname": "StockOption12Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption13Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 13 [Member]" } } }, "localname": "StockOption13Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption14Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 14 [Member]" } } }, "localname": "StockOption14Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption15Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 15 [Member]" } } }, "localname": "StockOption15Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 1 [Member]" } } }, "localname": "StockOption1Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 2 [Member]" } } }, "localname": "StockOption2Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 3 [Member]" } } }, "localname": "StockOption3Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 4 [Member]" } } }, "localname": "StockOption4Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 5 [Member]" } } }, "localname": "StockOption5Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 6 [Member]" } } }, "localname": "StockOption6Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 7 [Member]" } } }, "localname": "StockOption7Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 8 [Member]" } } }, "localname": "StockOption8Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockOption9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 9 [Member]" } } }, "localname": "StockOption9Member", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "domainItemType" }, "bivi_StockWarrantsClassifiedAsDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock warrants classified as derivative liability" } } }, "localname": "StockWarrantsClassifiedAsDerivativeLiability", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bivi_TotalOtherExpenseIncome": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "TotalOtherExpenseIncome", "totalLabel": "TOTAL OTHER (INCOME) EXPENSE, NET" } } }, "localname": "TotalOtherExpenseIncome", "nsuri": "http://nanoantibiotics.com/20210331", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r246", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_DirectorMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r90", "r187" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r14" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r53", "r54", "r55", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r46", "r97", "r102" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r50", "r81", "r83", "r87", "r92", "r152", "r154", "r172", "r213", "r221" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r27", "r50", "r92", "r152", "r154", "r172" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r11", "r50", "r92", "r152", "r154", "r172" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total other assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER\u00a0\u00a0ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation \u2013 Interim Financial Information" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r19", "r234", "r235" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets", "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net\u00a0\u00a0increase (decrease) in cash" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r24", "r107", "r216", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r104", "r105", "r106", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r53", "r54" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical", "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r109" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2021 and June 30, 2020; 13,957,792 and 5,204,392 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r78", "r79", "r89", "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r78", "r79", "r89", "r170", "r171", "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepositLiabilitiesAccruedInterest": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued but unpaid interest on deposit liabilities.", "label": "Capitalized Accured Interest" } } }, "localname": "DepositLiabilitiesAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/EquityTransactionsDetails3", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/EquityTransactionsDetails3", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r28", "r31", "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "periodEndLabel": "Balance at March 31, 2021", "periodStartLabel": "Beginning balance at July 1, 2020" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Equity Transactions" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET (LOSS) INCOME PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r36", "r58", "r59", "r60", "r61", "r62", "r66", "r68", "r70", "r71", "r72", "r75", "r76", "r218", "r227" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "- Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON\u00a0\u00a0SHARES OUTSTANDING" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r36", "r58", "r59", "r60", "r61", "r62", "r68", "r70", "r71", "r72", "r75", "r76", "r218", "r227" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "- Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r49", "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net (loss) income per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r53", "r54", "r55", "r57", "r63", "r65", "r77", "r93", "r109", "r110", "r141", "r142", "r143", "r148", "r149", "r173", "r174", "r175", "r176", "r177", "r178", "r228", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r162", "r163", "r164", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r163", "r194", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r111", "r112", "r117", "r119", "r163", "r194" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r111", "r112", "r117", "r119", "r163", "r195" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r163", "r196" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r165", "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "activity for liabilities measured at fair value using unobservable inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in in fair value of level 3 liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r166" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Additions to level 3 liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Transfer in and/or out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r194", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetails", "http://nanoantibiotics.com/role/FairValueMeasurementsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r101" ], "calculation": { "http://nanoantibiotics.com/role/IntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Year ending June 30, 2021 (Remaining three months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r101", "r199" ], "calculation": { "http://nanoantibiotics.com/role/IntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intellectual Property" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r101", "r198" ], "calculation": { "http://nanoantibiotics.com/role/IntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nanoantibiotics.com/role/IntangibleAssetsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intellectual Property, Net", "totalLabel": "Intellectual Property, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsDetails", "http://nanoantibiotics.com/role/IntangibleAssetsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r46", "r219" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "bivi_TotalOtherExpenseIncome", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain (Loss) on Sale of Derivatives", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r94", "r95", "r212" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r37" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "totalLabel": "NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "verboseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r96", "r99" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r34", "r80", "r180", "r181", "r220" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "bivi_TotalOtherExpenseIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "bivi_TotalOtherExpenseIncome", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r41", "r43", "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r21", "r50", "r84", "r92", "r153", "r154", "r155", "r172" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r50", "r92", "r172", "r214", "r224" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS'\u00a0\u00a0EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r50", "r92", "r153", "r154", "r155", "r172" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Loan payable" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r42" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r42", "r44", "r47" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r32", "r33", "r35", "r47", "r50", "r56", "r58", "r59", "r60", "r61", "r64", "r65", "r69", "r81", "r82", "r85", "r86", "r88", "r92", "r172", "r217", "r226" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "NET (LOSS) INCOME", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SCHEDULE OF NON-CASH FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/EquityTransactionsDetails3", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r81", "r82", "r85", "r86", "r88" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Background Information" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BackgroundInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER (INCOME) EXPENSE:" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r39" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r39" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r40" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from loan payable - related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r118", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r118", "r184", "r188", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r182", "r183", "r185", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r147", "r236" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r110", "r144", "r223", "r231", "r232" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r53", "r54", "r55", "r57", "r63", "r65", "r93", "r141", "r142", "r143", "r148", "r149", "r228", "r230" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "number of outstanding stock options and warrants" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "summarizes the warrants activity" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "At March 31, 2021 and June 30, 2020, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r98", "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Summary of the intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r51", "r186", "r188" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r121", "r130", "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "activity relating to the Company\u2019s stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Estimated future amortization expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r38" ], "calculation": { "http://nanoantibiotics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation", "verboseLabel": "Share-based Payment Arrangement, Noncash Expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "verboseLabel": "Warrant Outstanding, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share", "verboseLabel": "Weighted Average Exercise Price, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Warrant Outstanding, at the beginning of the period", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Weighted Average Exercise Price, at the beginning of the period", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "periodEndLabel": "Weighted Average Exercise Price, at the end of period", "periodStartLabel": "Weighted Average Exercise Price, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Warrant Outstanding, at the end of period", "periodStartLabel": "Warrant Outstanding, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Life, at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.", "label": "Warrant Exercised - Acuitas" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-Free Interest Rate", "verboseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Non-vested Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r123", "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.", "label": "summary of stock options outstanding and exercisable by exercise price" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at end of period", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at beginning of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r135", "r145" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term", "verboseLabel": "Expected life of options (In years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails3" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r53", "r54", "r55", "r57", "r63", "r65", "r77", "r93", "r109", "r110", "r141", "r142", "r143", "r148", "r149", "r173", "r174", "r175", "r176", "r177", "r178", "r228", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r53", "r54", "r55", "r77", "r197" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of shares for services, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r109", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Net proceeds from issuance of common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of shares for interest payment, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r109", "r110", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Cashless exercise of options, Shares", "negatedLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common shares issued for service", "verboseLabel": "Issuance of shares for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r109", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common shares issued for interest payment", "verboseLabel": "Issuance of shares for interest payment" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows", "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r25", "r109", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Cashless exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r50", "r91", "r92", "r172" ], "calculation": { "http://nanoantibiotics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r50", "r53", "r54", "r55", "r57", "r63", "r92", "r93", "r110", "r141", "r142", "r143", "r148", "r149", "r150", "r151", "r156", "r172", "r173", "r174", "r178", "r229", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r179", "r192" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r179", "r192" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r179", "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r179", "r192" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r191", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary of Investment Holdings [Line Items]" } } }, "localname": "SummaryOfInvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails", "http://nanoantibiotics.com/role/EquityTransactionsDetails2", "http://nanoantibiotics.com/role/EquityTransactionsDetails3", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UnearnedPremiums": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.", "label": "Unearned Discount" } } }, "localname": "UnearnedPremiums", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/EquityTransactionsDetails4", "http://nanoantibiotics.com/role/EquityTransactionsDetailsNarrative", "http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r67", "r72" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "- Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r66", "r72" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "- Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nanoantibiotics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r237": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r238": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r239": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r241": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r242": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r243": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r244": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r245": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r246": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r247": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r248": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r249": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r251": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r252": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r253": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r254": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r255": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" } }, "version": "2.1" } ZIP 51 0001520138-21-000255-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-21-000255-xbrl.zip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end